Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 15518. Отображено 100.
27-05-2011 дата публикации

УСТРОЙСТВО ДЛЯ ЖИДКОФАЗНОГО ТЕРМИЧЕСКОГО ОКИСЛЕНИЯ ФТОРОЛЕФИНОВ

Номер: RU0000104870U1
Автор: Емельянов Геннадий Анатольевич, Костычева Дарья Михайловна, Кулаченков Сергей Анатольевич, Родин Виктор Михайлович
Принадлежит: Федеральное государственное унитарное предприятие "Ордена Ленина и ордена Трудового Красного Знамени научно-исследовательский институт синтетического каучука имени академика С.В. Лебедева"

Устройство для проведения жидкофазного термического окисления фторолефинов, включающее стальной реактор с патрубком, электрообогреватель, термопару и приспособление для регулирования температуры, отличающееся тем, что приспособление для регулирования температуры конструктивно выполнено в виде трубчатого змеевика, навитого на верхнюю часть реактора. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) 104 870 (13) U1 (51) МПК B01J 10/00 (2006.01) C07D 303/08 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21)(22) Заявка: 2010113819/04, 09.04.2010 (24) Дата начала отсчета срока действия патента: 09.04.2010 (45) Опубликовано: 27.05.2011 1 0 4 8 7 0 R U Формула полезной модели Устройство для проведения жидкофазного термического окисления фторолефинов, включающее стальной реактор с патрубком, электрообогреватель, термопару и приспособление для регулирования температуры, отличающееся тем, что приспособление для регулирования температуры конструктивно выполнено в виде трубчатого змеевика, навитого на верхнюю часть реактора. Ñòðàíèöà: 1 ru CL U 1 U 1 (54) УСТРОЙСТВО ДЛЯ ЖИДКОФАЗНОГО ТЕРМИЧЕСКОГО ОКИСЛЕНИЯ ФТОРОЛЕФИНОВ 1 0 4 8 7 0 Адрес для переписки: 198035, Санкт-Петербург, ул. Гапсальская, 1, ФГП "Ордена Ленина и ордена Трудового Красного Знамени НИИ синтетического каучука имени академика С.В. Лебедева", начальнику ИКЦ П.П. Шпакову (73) Патентообладатель(и): Федеральное государственное унитарное предприятие "Ордена Ленина и ордена Трудового Красного Знамени научноисследовательский институт синтетического каучука имени академика С.В. Лебедева" (RU) R U Приоритет(ы): (22) Дата подачи заявки: 09.04.2010 (72) Автор(ы): Емельянов Геннадий Анатольевич (RU), Родин Виктор Михайлович (RU), Костычева Дарья Михайловна (RU), Кулаченков Сергей Анатольевич (RU) U 1 U 1 1 0 4 8 7 0 1 0 4 8 7 0 R U R U Ñòðàíèöà: 2 RU 5 10 15 20 25 30 35 40 45 50 104 870 U1 Предложение относится к области технологии получения ...

Подробнее
Номер записи: 1
12-04-2012 дата публикации

Compounds for enzyme inhibition

Номер: US20120088762A1
Автор: Catherine Sylvain, Francesco Parlati, Guy J. Laidig, Han-Jie Zhou, Kevin D. Shenk, Mark K. Bennett, Mark S. Smyth
Принадлежит: Onyx Therapeutics Inc

One aspect of the invention relates to inhibitors that preferentially inhibit immunoproteasome activity over constitutive proteasome activity. In certain embodiments, the invention relates to the treatment of immune related diseases, comprising administering a compound of the invention. In certain embodiments, the invention relates to the treatment of cancer, comprising administering a compound of the invention.

Подробнее
Номер записи: 2
12-04-2012 дата публикации

Novel 3.2.1-bicyclo-octane compounds

Номер: US20120088922A1
Автор: Adam P. CLOSSON, Benjamin Amorelli, Nicole O'keefe
Принадлежит: International Flavors and Fragrances Inc

The present invention relates to novel compounds and their use in fragrance compositions. Novel 3.2.1-bicyclo-octane compounds of the present invention are represented by formula: wherein R is selected from the group consisting of carbonyl and [1,3]dioxolane; R′ is selected from the group consisting of hydrogen and allyl; or R and R′ taken together represent

Подробнее
Номер записи: 3
24-05-2012 дата публикации

Process for producing propylene oxide

Номер: US20120130096A1
Автор: Anna Forlin, Bruce D. Hook, David H. West, Hannah L. Crampton, Philip J. Carlberg, William W. Fan
Принадлежит: Individual

A multiple liquid phase composition and process for preparing propylene oxide including a reaction mixture of: (a) propylene, (b) at least one peroxide compound, (c) at least one catalyst, such as a titanium silicalite-1 (TS-I) catalyst, and (d) and a predetermined amount of a solvent mixture; wherein the solvent mixture comprises at least (i) at least one alcohol, such as methanol, and (ii) at least one non-reactive co-solvent; wherein the solvents are mixed at a predetermined concentration; wherein the non-reactive co-solvent has a different boiling point than propylene oxide; and wherein the resulting propylene oxide product partitions into a high affinity solvent during the reaction. The process of the present invention advantageously produces a waste stream with little or no significant amount of sodium chloride (NaCl).

Подробнее
Номер записи: 4
31-05-2012 дата публикации

Process

Номер: US20120136165A1
Автор: Basudeb Saha, David C. Sherrington, Krzysztof Ambroziak, Rene Mbeleck
Принадлежит: SOUTH BANK UNIVERSITY ENTERPRISES LTD

The present invention provides a continuous process for the epoxidation of an olefinic compound with an oxidant, which process comprises reaction of an olefinic compound with an oxidant in the presence of a catalyst in an apparatus that comprises a reactive distillation column, which column comprises (i) a reactive section, which comprises the catalyst (ii) a rectifying section situated above the reactive section and adapted to allow separation of reagents and/or by-products from products (ix) a stripping section situated below the reactive section and adapted to allow separation of product from reagents and/or by-products (x) a vessel situated below the stripping section and adapted to provide a source of heat for the column and in which initial vaporisation of one or more of the reagents can occur, wherein the temperature in the reactive section (i) is a temperature at which the reaction between the olefinic compound and the oxidant takes place and the temperature in the stripping section (iii) is higher than the temperature in the rectifying section (ii).

Подробнее
Номер записи: 5
05-07-2012 дата публикации

Compositions comprising functionalized carbon-based nanostructures and related methods

Номер: US20120171093A1
Автор: Ezequiel Schmois, John B. Goods, Joseph Walish, Stefanie Sydlik, Timothy M. Swager, Wiktor Lewandowski, William R. Collins
Принадлежит: Massachusetts Institute of Technology

The present invention generally relates to compositions comprising and methods for forming functionalized carbon-based nanostructures.

Подробнее
Номер записи: 6
30-08-2012 дата публикации

Furan-Based Curable Compound Derived from Biomass, Solvent-Free Curable Composition, and Method for Preparing Same

Номер: US20120220742A1
Автор: Baek Jin Kim, Bo Ra Kim, Do Hoon LEE, Jae Soung Lee, Jae Won Jung, Jin Ku Cho, Sang Hyeup Lee, Sang Yong Kim
Принадлежит: Korea Institute of Industrial Technology KITECH

The present invention relates to a furan-based curable compound derived from carbohydrate-based biomass, to a solvent-free curable composition, and to a method for preparing thereof, wherein the furan-based curable compound derived from biomass according to the present invention includes two epoxide functional groups bonded to at least one furan-based compound. The present invention may provide an environmentally friendly next-generation curable compound comprising a novel furan-based compound derived from biomass, which may be substituted for curable materials derived from oil resources, as a basic backbone, as well as a composition containing the same. According to the present invention, a curable material, which has a low contraction ratio during curing as compared to conventional radical-type curing materials, may be obtained, and a compound applied to the novel curing material may be prepared with a combination of excellent efficiency and cost-effectiveness.

Подробнее
Номер записи: 7
01-11-2012 дата публикации

Processes for making high purity renewable source-based plasticizers and products made therefrom

Номер: US20120277357A1
Автор: Erik Hagberg, George Poppe, Stephen D. Horton, Stephen Howard
Принадлежит: Archer Daniels Midland Co

Presently disclosed are high purity unsaturated fatty acid esters with an ester moiety characterized by having from five to seven members in a ring structure, which esters when epoxidized find particular utility as primary plasticizers in flexible polyvinyl halide applications. Also disclosed are processes for making the high purity esters.

Подробнее
Номер записи: 8
20-12-2012 дата публикации

4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs

Номер: US20120322875A1
Автор: Aihua Wang, Alan R. DeAngelis, Gee-Hong Kuo, Rui Zhang
Принадлежит: Individual

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as PPAR delta modulators to treat or inhibit the progression of, for example, dyslipidemia.

Подробнее
Номер записи: 9
03-01-2013 дата публикации

Preparation of 2,2-bis (fluoroalkyl) oxirane and preparation of photoacid generator therefrom

Номер: US20130005997A1
Автор: Koji Hasegawa, Masaki Ohashi, Masayoshi Sagehashi, Takeru Watanabe, Youichi Ohsawa
Принадлежит: Shin Etsu Chemical Co Ltd

A 2,2-bis(fluoroalkyl)oxirane (A) is prepared by reacting a fluorinated alcohol (1) with a chlorinating, brominating or sulfonylating agent under basic conditions to form an oxirane precursor (2) and subjecting the oxirane precursor to ring closure under basic conditions. R 1 and R 2 are fluoroalkyl groups, R 3 and R 4 are hydrogen or monovalent hydrocarbon groups, X is chlorine, bromine or —OSO 2 R 5 group, and R 5 is alkyl or aryl.

Подробнее
Номер записи: 10
09-05-2013 дата публикации

EPOXIDATION PROCESS

Номер: US20130116454A1
Автор: Buijink Jan-Karel Frederik
Принадлежит:

The present invention relates to an epoxidation process for the preparation of alkylene oxide comprising contacting a hydroperoxide with an olefin in the presence of a catalyst, wherein the catalyst is a titanium containing catalyst obtainable by a method comprising the steps of (a) making a support by a method comprising reacting a silicate with water in the presence of a surfactant selected from block copolymers based on ethylene oxide (EO) and propylene oxide (PO), and calcining the obtained re-action product; and (b) impregnating the support of step (a) with a titanium containing agent. 1. An epoxidation process for the preparation of alkylene oxide comprising contacting a hydroperoxide with an olefin in the presence of a catalyst , wherein the catalyst is a titanium containing catalyst obtainable by a method comprising the steps of:(a) making a support by a method comprising reacting a silicate with water in the presence of a surfactant selected from block copolymers based on ethylene oxide (EO) and propylene oxide (PO), and calcining the obtained reaction product; and(b) impregnating the support of step (a) with a titanium containing agent.2. A process according to claim 1 , wherein the silicate in step (a) is an orthosilicate of formula Si(OR) claim 1 , wherein each R is the same or different claim 1 , and is an alkyl.3. A process according to claim 1 , wherein the surfactant is selected from block copolymers based on ethylene oxide (EO) and propylene oxide (PO) containing 2 hydroxyl groups.4. A Process according to claim 1 , wherein the surfactant is selected from EO/PO-block copolymers having the general formula HO(CHCHO)(CHCH(CH)O)(CHCHO)H claim 1 , wherein x is an integer in the range of from 15 to 150.5. A process according to claim 1 , wherein the surfactant have the chemical formula selected from HO(CHCHO)(CHCH(CH)O)(CHCHO)H or HO(CHCHO)(CHCH(CH)O)(CHCHO)H.6. A process according to claim 1 , wherein the calcining in step (a) comprises heating the ...

Подробнее
Номер записи: 11
09-05-2013 дата публикации

CLEAN, HIGH-YIELD PREPARATION OF S,S AND R,S AMINO ACID ISOSTERES

Номер: US20130116457A1
Автор: Clement Todd E., III James, Malik Aslam A., Palandoken Hasan, Robinson, Stringer Joy A.
Принадлежит: Aerojet Fine Chemicals LLC

The present invention provides compounds and methods that can be used to convert the intermediate halomethyl ketones (HMKs), e.g., chloromethyl ketones, to the corresponding S,S- and R,S-diastereomers. More particularly, the present invention provides: (1) reduction methods; (2) inversion methods; and (3) methods involving the epoxidation of alkenes. Using the various methods of the present invention, the R,S-epoxide and the intermediary compounds can be prepared reliably, in high yields and in high purity. 175.-. (canceled)77. The composition in accordance with claim 76 , wherein said non-chelating claim 76 , bulky reducing agent used in said method is a member selected from the group consisting of lithium aluminum t-butoxyhydride (LATBH) and sodium tris-t-butoxyborohydride (STBH).78. The method in accordance with claim 77 , wherein said non-chelating claim 77 , bulky reducing agent is lithium aluminum t-butoxyhydride (LATBH).79. The composition in accordance with claim 76 , wherein Ris a member selected from the group consisting of a benzyl group claim 76 , an S-phenyl group claim 76 , an alkyl group and para-nitrobenzene.80. The composition in accordance with claim 76 , wherein Xis a halogen.81. The composition in accordance with claim 80 , wherein Xis chloro or bromo.82. The composition in accordance with claim 76 , wherein Ris a blocking group selected from the group consisting of BOC claim 76 , MOC and CBZ.83. The composition in accordance with claim 76 , wherein the reduction is carried out in a solvent selected from the group consisting of diethyl ether claim 76 , THF claim 76 , MTBE claim 76 , glyme and diglyme.84. The composition in accordance with claim 83 , wherein said solvent is diethyl ether.85. The composition in accordance with claim 76 , wherein the reduction is carried out at a temperature ranging from about −30° C. to about 25° C.86. The composition in accordance with claim 85 , wherein the reduction is carried out at a temperature ranging from ...

Подробнее
Номер записи: 12
16-05-2013 дата публикации

Plasticizers Made from Oil Extracted from Microorganisms and Polar Polymeric Compositions Comprising the Same

Номер: US20130123408A1
Автор: Eaton Robert F., Han Suh Joon, Maurer Brian R., Zinkweg Dirk B.
Принадлежит:

Plasticizers are made from oil with a narrowed, fatty acid polydispersity and extracted from a microorganism, such as a natural or genetically modified bacterium or algae. These plasticizers can comprise either a large content of either saturated C4 and/or C6 triglycerides or unsaturated C12 or greater triglycerides that have been chemically modified by one or more of epoxidation, acylation and esterification. The plasticizers of this invention are particularly well-suited for use with polar polymeric resins such as PVC. 1. A process for making a plasticizer , comprising:extracting oil from a microorganism, the extracted oil having a narrowed, fatty acid polydispersity of less than 5 wt % saturated fatty acids and less than 5 wt % fatty acids with 20 or more carbon atoms, andconverting the extracted oil to the plasticizer, (i) a solubility in PVC of greater than 40 parts per hundred resin (phr) at 90° C.,', '(ii) liquidity at ambient temperature (23° C.),', '(iii) a weight average molecular weight (Mw) of 250 or greater, and', '(iv) an iodine number of 10 or less., 'the plasticizer having at least one of2. The process of in which the oil is extracted from a microorganism selected from the group consisting of bacteria claim 1 , algae claim 1 , yeast claim 1 , mold claim 1 , slime and plankton.3. The process of in which extracting the oil comprises extracting an epoxidized oil from the microorganism.4. The process of in which the microorganism is genetically modified to produce said epoxidized oil.5. The process of in which the oil consists essentially of saturated Cand/or Ctriglycerides.6. The process of in which converting the extracted oil to the plasticizer comprises a purifying process.7. The process of in which the extracted oil comprises unsaturated Cor greater triglycerides claim 1 , and{'sub': '12', 'converting the extracted oil to the plasticizer comprises chemically modifying the unsaturated Cor greater triglycerides such that the plasticizer has at least ...

Подробнее
Номер записи: 13
16-05-2013 дата публикации

Adhesive Compositions for Bonding Composites

Номер: US20130123513A1
Автор: Rammon Richard M., Williamson Bobby Lee
Принадлежит: GEORGIA-PACIFIC CHEMICALS LLC

The present invention relates to a non-thermosetting composition made by reacting epichlorohydrin and a primary amine, to the use of that composition for making thermosetting (curable) adhesives suitable for bonding composites, to a method of preparing composites using the thermosetting (curable) adhesives, and to the related composites bonded with the thermosetting (curable) adhesives. 1. A non-thermosetting, reaction product of (a) epichlorohydrin and (b) an amine selected from the group consisting of ammonia, a primary amine and mixtures thereof, wherein the reaction product is produced by reacting the epichlorohydrin and the amine in a ratio of 0.40 to 0.92 moles of epichlorohydrin per atom equivalent of amine hydrogen and wherein the epi-amine reaction product is produced by reacting in a serial fashion separate portions of the epichlorohydrin and separate portions of the amine at a temperature of not greater than 60° C. This application is a divisional of co-pending U.S. patent application Ser. No. 12/718,391, filed on Mar. 5, 2010, which claims the benefit of U.S. Provisional Application No. 61/158,013 filed Mar. 6, 2009, each of which is hereby incorporated by reference in its entirety.The present invention is directed to a non-thermosetting composition made by reacting epichlorohydrin and an amine, to the use of that composition for making thermosetting (curable) adhesives, particularly adhesives suitable for bonding composites, to a method of preparing composites, particularly wood composites using the thermosetting (curable) adhesives, and to the related composites bonded with the cured thermosetting (curable) adhesives.A variety of composite materials are made by bonding into a unitary product a primary constituent, often a structural or reinforcement component, using a bonding agent or matrix material, such as an adhesive resin. Composites include engineered wood products (wood-adhesive composite products), insulation products and the like.Wood-adhesive ...

Подробнее
Номер записи: 14
23-05-2013 дата публикации

PROCESSES AND INTERMEDIATES FOR PREPARING STERIC COMPOUNDS

Номер: US20130131359A1
Автор: Chen Minzhang, Forslund Raymond E., Jung Young Chun, Tanoury Gerald J.
Принадлежит: VERTEX PHARMACEUTICALS INCORPORATED

This invention relates to processes and intermediates for the preparation of an alpha-amino beta-hydroxy acid of Formula 1 2. The process of claim 1 , wherein R claim 1 , is C-Calkyl claim 1 , R′is H and R′is —NHRwherein Ris C-Calkyl or C-Ccycloalkyl.3. The process of claim 2 , wherein Ris propyl and Ris cyclopropyl.5. The process of claim 4 , wherein the aminating reagent is an azide salt and the intermediate azido compound is reduced by hydrogenation.7. The process of claim 6 , wherein the oxidizing reagent is t-butyl hydroperoxide.8. The process of claim 6 , wherein the oxidizing reagent includes a chiral reagent.9. The process of claim 8 , wherein the oxidizing reagent is a mixture of samarium (III) isopropoxide claim 8 , triphenyl arsine oxide claim 8 , S-(−)1 claim 8 ,1′-bi-2-naphthol and 4 Å molecular sieves.10. The process of claim 6 , wherein the oxidizing reagent is urea-hydrogen peroxide in the presence of trifluoroacetic anhydride.11. The process of claim 6 , wherein R′is —OE.12. The process of claim 6 , wherein Ris —NHR.13. The process of claim 11 , further comprising hydrolyzing the compound of Formula ii to give an acid and then converting the acid to an amide compound of Formula ii wherein R′is —NHR.15. The process of claim 14 , wherein the compound of Formula 1 is (2S claim 14 ,3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide.16. The process of claim 14 , wherein the organic acid is L-tartaric acid.17. The process of claim 14 , wherein the organic acid is deoxycholic acid.18. A compound which is N-cyclopropyl-3-propyloxirane-2-carboxamide.19. A compound which is N-cyclopropyl-3-propyloxirane-2-carboxamide.20. A compound which is 3-azido-N-cyclopropyl-2-hydroxyhexanamide.21. A compound which is 3-amino-N-cyclopropyl-2-hydroxyhexanamide claim 14 , L-tartaric acid salt.22. A compound which is 3-amino-N-cyclopropyl-2-hydroxyhexanamide claim 14 , deoxycholic acid salt. This application claims the benefits of U.S. Provisional Application Ser. No. 60/782,976, ...

Подробнее
Номер записи: 15
06-06-2013 дата публикации

ACTIVITY BASED PROBES (ABPs) INTERACTING WITH GLYCOSIDASES

Номер: US20130143228A1
Автор: Aerts Johannes Maria Franciscus Gerardus, Overkleeft Herman Steven
Принадлежит:

An activity based probe (ABP) comprising a glycosidase inhibitor, and a detection-group. The ABPs of the inventions are used for diagnosing storage disorder for screening of compounds suitable for preventing and/or treating a storage disorder, for monitoring of therapeutic enzymes for lysosomal storage disorders, and for ultra-sensitive visualization of glycosidase-fusion proteins in molecular imaging. 1. An activity based probe (ABP) comprising a glycosidase inhibitor and a detection-group , wherein the glycosidase inhibitor covalently binds to a glycosidase and/or a glycosidase fusion protein , wherein the glycosidase is optionally a glucocerebrosidase.2. The ABP according to claim 1 , wherein said glycosidase inhibitor is a glucocerebrosidase inhibitor optionally comprising cyclophellitol and/or an analogue thereof.4. The ABP according to claim 1 , wherein said detection group is a fluorophore or biotine.5. A method for producing an ABP according to claim 1 , said method comprising chemically modifying said glycosidase inhibitor and linking said glycosidase inhibitor to a detection-group.6. The method for producing an ABP according to claim 5 , wherein said glycosidase inhibitor is cyclophellitol claim 5 , which is physically linked to a fluorophore or biotine.7. The method for producing an ABP according to claim 6 , wherein azido-cyclophellitol is linked to a fluorophore or biotine.8. A method for detecting an ABP according to claim 1 , said method comprising:binding a modified glycosidase inhibitor to a glycosidase and/or a glycosidase-fusion protein, anddetecting the bound inhibitor via a detection group that is in physical linkage with said inhibitor, optionally wherein said detection group comprises a fluorophore or biotine connected to said inhibitor.9. An ABP according to claim 1 , capable of being used in detecting and/or quantifying activity of an active enzyme claim 1 , for screening of a compound for use thereof in treating and/or preventing a storage ...

Подробнее
Номер записи: 16
06-06-2013 дата публикации

EPOXY COMPOUND, CURABLE COMPOSITION, AND CURED PRODUCT THEREOF

Номер: US20130144030A1
Автор: Satou Yutaka
Принадлежит: DIC CORPORATION

A problem to be solved by the invention is to provide a novel epoxy resin exhibiting excellent performance with respect to heat resistance and low thermal expansibility of a cured product, a curable composition using the same, and a cured product having excellent heat resistance and low thermal expansibility. The curable composition contains an epoxy compound and a curing agent as essential components, a calixarene-type novel epoxy compound being used as the epoxy compound. The novel epoxy compound has a resin structure represented by structural formula 1 below (in the formula, Rs each independently represent a hydrogen atom, an alkyl group, or an alkoxy group, and n is a repeat unit and an integer of 2 to 10). 2. A curable resin composition comprising an epoxy compound (A) and a curing agent (B) as essential components claim 1 , wherein the novel epoxy compound according to is used as the epoxy compound (A).3. The curable composition according to claim 2 , wherein in addition to the epoxy compound (A) and the curing agent (B) claim 2 , a naphthalene-based epoxy resin (A′) other than the epoxy compound (A) is used.4. The curable resin composition according to claim 3 , wherein the ratio between the epoxy compound (A) and the naphthol novolac epoxy resin (A′) present is such that the content ratio of the naphthalene-based epoxy resin (A′) other than the epoxy compound (A) is 3 to 50% in terms of area ratio in GPC measurement of a mixture of both.5. A cured product produced by a curing reaction of the curable composition according to .6. A cured product produced by a curing reaction of the curable composition according to .7. A cured product produced by a curing reaction of the curable composition according to . The present invention relates to an epoxy compound which produces a cured product having excellent heat resistance and low thermal expansibility and which can be preferably used for applications such as a printed circuit board, a semiconductor encapsulant, a ...

Подробнее
Номер записи: 17
13-06-2013 дата публикации

Crystalline Peptide Epoxy Ketone Protease Inhibitors and the Synthesis of Amino Acid Keto-Epoxides

Номер: US20130150289A1
Автор: Fuller William Dean, LAIDIG Guy J., Phiasivongsa Pasit, Sehl Louis C.
Принадлежит: Onyx Therapeutics, Inc.

The invention relates to crystalline peptide keto epoxide compounds, methods of their preparation, and related pharmaceutical compositions. This invention also relates to methods for the preparation of amino acid keto-epoxides. Specifically, allylic ketones are stereoselectively converted to the desired keto epoxides. 118.-. (canceled)20. A method of claim 19 , wherein the organic solvent is selected from diethyl ether claim 19 , THF claim 19 , acetonitrile claim 19 , and MTBE claim 19 , or any combination thereof.21. A method of claim 20 , wherein the organic solvent is a mixture of THF and acetonitrile.22. A method of claim 19 , wherein bringing the solution to supersaturation comprises slow addition of an anti-solvent claim 19 , allowing the solution to cool claim 19 , reducing the volume of the solution claim 19 , or any combination thereof.23. A method of claim 22 , wherein bringing the solution to supersaturation comprises cooling the solution to ambient temperature or lower.24. A method of claim 19 , further comprising washing the crystals.25. A method of claim 24 , wherein the washing comprises washing with a liquid selected from diethyl ether claim 24 , THF claim 24 , acetonitrile claim 24 , and MTBE claim 24 , or any combination thereof.26. A method of claim 25 , wherein washing comprises washing with acetonitrile.27. A method of claim 19 , wherein isolating the crystals comprises filtering the crystals.28. A method of claim 19 , further comprising drying the crystals under reduced pressure.30. A crystalline salt of claim 29 , having a DSC thermogram substantially as shown in .31. A crystalline salt of claim 29 , having a melting point of about 180 to about 190° C.32. A crystalline salt of claim 31 , having a melting point of about 184 to about 188° C.33. A crystalline salt of claim 29 , having an XRPD pattern substantially as shown in .34. A crystalline salt of claim 29 , having 2θ values 4.40; 7.22; 9.12; 12.36; 13.35; 14.34; 15.54; 16.14; 16.54; 17.00; ...

Подробнее
Номер записи: 18
20-06-2013 дата публикации

BIOCOMPATIBLE BIODEGRADABLE FUMAGILLIN ANALOG CONJUGATES

Номер: US20130158046A1
Автор: Akullian Laura C., Hammond Charles E., Kane John J., Petter Russell C., Stevenson Cheri A., Yin Mao, Yurkovetskiy Aleksandr
Принадлежит: Mersana Therapeutics, Inc

Fumagillin analog polymer conjugates, methods of making fumagillin analog polymer conjugates, compositions comprising a polymer conjugate of a fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a polymer conjugate of a fumagillin analog, are described. Also described are novel fumagillin analogs, methods of making fumagillin analogs, compositions comprising at least one fumagillin analog, and methods for treating cancer, or treating angiogenic diseases comprising administering to a subject in need thereof an effective amount of a fumagillin analog. 124.-. (canceled)2631.-. (canceled)32. A composition comprising the compound or pharmaceutically acceptable salt of the compound of and a pharmaceutically acceptable carrier.3335.-. (canceled)36. A composition comprising a compound or pharmaceutically acceptable salt of the compound of and a pharmaceutically acceptable carrier.37. The composition of claim 36 , wherein the pharmaceutically acceptable carrier is suitable for injectable administration and the composition comprises an injectable dosage form.38. A method of treating cancer claim 25 , comprising administering to a subject in need thereof a compound or a pharmaceutically acceptable salt of a compound of claim 25 , in an amount effective to treat the cancer.39. The method of claim 38 , wherein the cancer is selected from the group consisting of anal claim 38 , astrocytoma claim 38 , leukemia claim 38 , lymphoma claim 38 , head and neck claim 38 , liver claim 38 , testicular claim 38 , cervical claim 38 , sarcoma claim 38 , hemangioma claim 38 , esophageal claim 38 , eye claim 38 , laryngeal claim 38 , mouth claim 38 , mesothelioma claim 38 , skin claim 38 , myeloma claim 38 , oral claim 38 , rectal claim 38 , throat claim 38 , bladder claim 38 , breast claim 38 , uterus claim 38 , ovary claim 38 , prostate claim 38 , lung claim 38 , colon claim 38 , ...

Подробнее
Номер записи: 19
04-07-2013 дата публикации

Process for superabsorbent polymer and crosslinker composition

Номер: US20130172180A1
Автор: Christoph Loick, Frank Schubert, Matthias Naumann, Stanley A. McIntosh
Принадлежит: Evonik Stockhausen LLC

The present invention further relates to a process to make a superabsorbent polymer comprising the steps of a) preparing a neutralized monomer solution comprising a polymerizable monomer selected from unsaturated acid groups-containing monomers, ethylenically unsaturated carboxylic acid anhydride, salts, or derivatives thereof and a caustic agent selection from an alkali agent, wherein the polymerizable monomer is neutralized to from about 50 mol % to about 85 mol %; b) forming a crosslinker monomer mixture by adding an internal crosslinker composition to the neutralized monomer solution wherein the internal crosslinking composition is the reaction product of a stoichiometric excess of amine with a glycidyl compound, wherein the internal crosslinker composition has a residual amount of glycidyl compounds of less than about 500 ppm based on the mass of the internal crosslinker composition; and c) polymerizing the crosslinker monomer mixture to make a superabsorbent polymer.

Подробнее
Номер записи: 20
18-07-2013 дата публикации

Derivative of epichlorohydrin of natural origin

Номер: US20130184477A1
Автор: GILBEAU Patrick
Принадлежит: SOLVAY SA

Derivative of epichlorohydrin of natural origin, selected from the group consisting of glycidyl ethers presenting an epoxide equivalent weight higher than or equal to 50 g/equivalent and lower than or equal to 15000 g/equivalent, of glycidyl esters, of glycidyl amides, of glycidyl imides, of glycidyl amines, and of any mixture thereof, and of which the C mass content is such that the ratio C/C is higher than 0.7 10. 1. A derivative of epichlorohydrin of natural origin , selected from the group consisting of glycidyl ethers , glycidyl esters , glycidyl amides , glycidyl imides , glycidyl amines , and any mixture thereof ,wherein said glycidyl ethers present an epoxide equivalent weight higher than or equal to 50 g/equivalent and lower than or equal to 15000 g/equivalent, and{'sup': 14', '14', '12', '−12, 'wherein the C mass content of said derivative of epichlorohydrin of natural origin is such that the ratio of C/C is higher than 0.7 10.'}2. The derivative of epichlorohydrin of natural origin according to selected from the group consisting of glycidyl ethers.3. The derivative of epichlorohydrin of natural origin according to wherein said glycidyl ether further exhibits characteristics selected from the group consisting ofan epoxy value in equivalent per 100 g of derivative higher than or equal to 0.008 and lower than or equal to 1.0,a dynamic viscosity at 25° C. higher than or equal to 50 mPa·s and lower than or equal to 50000,a content of hydrolysable chloride higher than or equal to 0.01% and lower than or equal to 2.2%, andany combination thereof.4. The derivative of epichlorohydrin of natural origin according to wherein said glycidyl ether exhibits an epoxy value in equivalent per 100 g of derivative higher than or equal to 0.008 and lower than or equal to 1.0.5. The derivative of epichlorohydrin of natural origin according to wherein said glycidyl ether exhibits a dynamic viscosity at 25° C. higher than or equal to 50 mPa·s and lower than or equal to 50000.6. ...

Подробнее
Номер записи: 21
25-07-2013 дата публикации

Use of fucoxanthin in the preparation of product for improving memory and having neuroprotective effect associated with neurodegenerative disorder

Номер: US20130189382A1
Автор: Li Liang, Li Yanmei
Принадлежит: Beijing Gingko Group Biological Technology Co., Ltd.

Use of fucoxanthin in the preparation of a product having neuroprotective effect associated with neurodegenerative disorder and improving memory is disclosed in the disclosure. A product having neuroprotective effect associated with neurodegenerative disorder is also disclosed in the disclosure. Fucoxanthin can inhibit oxidative stress of cells and has the effect of preventing or treating Alzheimer's disease and improving memory. 1. Use of fucoxanthin in the preparation of a product having neuroprotective effect associated with neurodegenerative disorder , wherein the product includes a food , a healthcare product and a drug.2. The use according to claim 1 , wherein the neurodegenerative disorder includes claim 1 , Parkinson's disease claim 1 , and Huntington's disease.3. The use according to claim 2 , wherein the product further has a memory-improving effect.4. The use of fucoxanthin according to claim 1 , wherein the source of fucoxanthin includes a plant source claim 1 , a microorganism source claim 1 , or a synthetic compound source.5. The use of fucoxanthin according to claim 4 , wherein the plant source of fucoxanthin is seaweed claim 4 , selected from a group consisting of laminaria japonica claim 4 , gulfweed claim 4 , wrack claim 4 , myosoton aquaticum claim 4 , colpomenia peregrina claim 4 , chorda filum claim 4 , wakame claim 4 , giant kelp claim 4 , carageen claim 4 , sargassum miyabei yendo claim 4 , hijiki claim 4 , sargassum pallidum claim 4 , and diatom.6. The use of fucoxanthin according to claim 1 , wherein the content of fucoxanthin in the product is 0.0001% to 60%; preferably claim 1 , the content of fucoxanthin in the product is 0.0001% to 10%.7. (canceled)8. The use of fucoxanthin according to claim 1 , wherein the content of fucoxanthin in a fucoxanthin extract is 90% to 100%; preferably claim 1 , the content of fucoxanthin in a fucoxanthin extract is 95% to 100%.9. (canceled)10. The use of fucoxanthin according to claim 1 , wherein 0.001 mg ...

Подробнее
Номер записи: 22
25-07-2013 дата публикации

EPICHLOROHYDRIN, MANUFACTURING PROCESS AND USE

Номер: US20130190474A1
Автор: BALTHASART Dominique, Boulos Noel, GILBEAU Patrick, Krafft Philippe
Принадлежит: SOLVAY SA

A method for the manufacture of a material selected from epoxy resins, glycidyl esters, glycidyl ethers, glycidyl amides, glycidyl imides, epichlorohydrin elastomers, coagulants, wet-strength resins, cationization agents, flame retardants and detergent ingredients by subjecting a product containing epichlorohydrin and trichloropropane to a reaction in order to obtain the material, wherein the product contains a positive amount of trichloropropane in an amount of up to less than 0.01 g of trichloropropane per kg of product. 1. A method for the manufacture of a material selected from the group consisting of epoxy resins , glycidyl esters , glycidyl ethers , glycidyl amides , glycidyl imides , epichlorohydrin elastomers , coagulants , wet-strength resins , cationization agents , flame retardants and detergent ingredients comprising subjecting a product comprising epichlorohydrin and trichloropropane to a reaction in order to obtain said material , wherein the product comprises a positive amount of trichloropropane in an amount of up to less than 0.01 g of trichloropropane per kg of product.2. The method according to claim 1 , wherein said method is a method for the manufacture of a material selected from the group consisting of epoxy resins claim 1 , glycidyl esters claim 1 , glycidyl ethers claim 1 , glycidyl amides claim 1 , glycidyl imides claim 1 , and epichlorohydrin elastomers.3. The method according to claim 1 , wherein said product further comprises at least one or more of the following compounds:(A) halogenated hydrocarbon compounds different from trichloropropane chosen from chloropropene, trichloropropene, chloropropanol, chloropropenol, dichloropropene, dichloropropane, dichloropropanol, monochloropropanediol, chloroethers, monochlorobenzene, and any mixture of at least two of them, and/or(B) compounds chosen from acrolein, methyl glycidyl ether, chloroacetone, glycerol, hydroxyacetone, glycidol, cyclopentanone and any mixture of at least two of them.4. The ...

Подробнее
Номер записи: 23
08-08-2013 дата публикации

Flexible dry sprinklers

Номер: US20130199803A1
Автор: Thomas Multer
Принадлежит: Reliable Automatic Sprinkler Co Inc

A dry sprinkler is provided having a flexible tube section having openings at opposite ends of the flexible tube section. The sprinkler includes a supply line connection at one end of the tube section, the supply line connection having an opening to receive fluid from the supply line. The sprinkler has a first seal sealed with the supply line connection to prevent fluid from the supply from entering the tube section. A sprinkler head is coupled to the tube section at another end of the tube section opposite the supply line connection, the sprinkler head having a deflector, a second seal sealing an output orifice of the sprinkler head, and a thermally responsive element arranged to maintain the second seal sealed. A fluid is contained in the tube between the first seal and the second seal, wherein the fluid is not susceptible to freezing. The thermally responsive element is constructed to release the second seal in response to an elevated temperature condition, to permit the release of the fluid in the tube and release the first seal to move toward the sprinkler head.

Подробнее
Номер записи: 24
15-08-2013 дата публикации

Method for producing oxidized olefin through olefin epoxidation

Номер: US20130211112A1
Автор: Bin Zhu, Chijian He, Hua Li, Jizao Gao, MIN Lin, Shuanghua Wan, Wei Wang, Xiaoju Wu, Xingtian Shu
Принадлежит: China Petroleum and Chemical Corp

A process for producing an alkylene oxide by olefin epoxidation, wherein said process comprises the steps of: (1) in a first olefin epoxidation condition, in the presence of a first solid catalyst, a first mixed stream containing a solvent, an olefin and H 2 O 2 is subjected to an epoxidation in one or more fixed bed reactors and/or one or more moving bed reactors until the conversion of H 2 O 2 reaches 50%-95%, then, optionally, the resulting reaction mixture obtained in the step (1) is subjected to a separation to obtain a first stream free of H 2 O 2 and a second stream containing the unreacted H 2 O 2 , and the olefin is introduced to the second stream to produce a second mixed stream, or optionally, the olefin is introduced to the reaction mixture obtained in the step (1) to produce a second mixed stream; (2) in a second olefin epoxidation condition, the reaction mixture obtained in the step (1) or the second mixed stream obtained in the step (1) and a second solid catalyst are introduced to one or more slurry bed reactors to conduct an epoxidation until the total conversion of H 2 O 2 reaches 98% or more, with a proviso that said process for producing the alkylene oxide by olefin epoxidation has an selectivity for the alkylene oxide of 90% or more. The process of the present invention combines the slurry bed reactor with the fixed bed reactor and/or the moving bed reactor so as to overcome the disadvantages of the low conversion of H 2 O 2 in the case that only the fixed bed reactor and/or the moving bed reactor are used, and the low selectivity for the target alkylene oxide in the case that only the slurry bed reactor is used.

Подробнее
Номер записи: 25
19-09-2013 дата публикации

MITOCHONDRIAL TARGETED STIMULATORS OF APOPTOSIS

Номер: US20130244325A1
Автор: GANGADHAR Nidhi, KELKAR Anshuman, SANDU Cristinel, STELLER Hermann
Принадлежит: THE ROCKEFELLER UNIVERSITY

Pro-apoptotic compounds having a tripartite structure: 5. A compound according to of formula A-L-B claim 1 , wherein B is chosen from Bcl2 inhibitors; monoamine oxidase inhibitors; and VDAC inhibitors.11. A method for inducing cell apoptosis comprising a exposing said cell to a compound according to .12. A method for inhibiting tumor growth comprising exposing said tumor to a compound according to . This application claims priority to U.S. Provisional Patent Application No. 61/533,288, filed Sep. 12, 2011, which is hereby incorporated herein by reference in its entirety.The following invention was made with Government support under contract number 5RO1 GM060124-12 awarded by NIH. The Government has certain rights in this invention.The invention relates to compounds that bind to and inhibit Inhibitor of Apoptosis (IAP) Proteins on the mitochondrial outer membrane. Therefore, these compounds are useful to induce apoptosis in cells and to inhibit the growth of tumors.Inhibitor of Apoptosis (IAP) proteins are commonly over-expressed in human tumors and thereby contribute to tumor cell survival. As a result, IAPs have become attractive drug targets in cancer therapy. Several small molecules targeting IAPs are in clinical trials. The design of these compounds is based on a short IAP-binding motif (IBM) that is present in natural IAP-antagonists, such as Reaper/Hid/Grim and mammalian Smac. Derivatives of the Hid IBM have proven most effective. They are reviewed in Vaux, D. L. (2009). 1:79, the contents of which are incorporated herein by reference. Although these IBM-mimetics show some promise, they have some serious limitations. In particular, all available compounds primarily target cIAP1/2, but are poor inhibitors of XIAP. Improved targeting of XIAP would be desirable, since this protein is a potent cell death inhibitor that is over-expressed in human tumors. It has been shown that inactivation of XIAP protects against tumorigenesis in the mouse, and that loss of the ...

Подробнее
Номер записи: 26
03-10-2013 дата публикации

Fatty Acid Inhibitors

Номер: US20130261099A1
Автор: Branchaud Bruce
Принадлежит: LIFE TECHNOLOGIES CORPORATION

Fatty acid inhibitors, pharmaceutical compositions including fatty acid inhibitors, methods for using fatty acid inhibitors to treat a variety of diseases, and methods for preparing fatty acid inhibitors are provided herein. 2. The compound of claim 1 , wherein the unsaturated or polyunsaturated fatty acid comprises an aliphatic chain having 5 to 23 carbons.3. The compound of claim 1 , wherein the unsaturated or polyunsaturated fatty acid is selected from a glycolipid claim 1 , a glycerolipid claim 1 , a phospholipid and a cholesterol ester.4. The compound of claim 1 , wherein Ris nitro (—NO).5. The compound of claim 1 , wherein the one or more electron withdrawing group is positioned on an alpha carbon of a carbon-carbon double bond of the non-naturally occurring claim 1 , unsaturated or polyunsaturated fatty acid.6. The compound of claim 1 , wherein a carbon-carbon double bond associated with Ris in cis configuration.7. The compound of claim 1 , wherein a carbon-carbon double bond associated with Ris in trans configuration.8. The compound of claim 1 , wherein the unsaturated or polyunsaturated fatty acid comprises two or more conjugated carbon-carbon double bonds.9. The compound of claim 8 , wherein Ris at any carbon in the two or more conjugated carbon-carbon double bonds.10. The compound of claim 1 , wherein at least Ris positioned at C-9 claim 1 , C-10 claim 1 , C-12 claim 1 , C-13 or a combination thereof.11. The compound of claim 1 , further comprising one or more non-carbon-carbon linkage selected from an ester linkage claim 1 , an ether linkage claim 1 , and a vinyl ether linkage.12. The compound of claim 1 , further comprising one or more functional group other than an electron withdrawing group positioned at any carbon of the unsaturated or polyunsaturated fatty acid.13. The compound of claim 1 , further comprising a pharmaceutically acceptable carrier claim 1 , excipient claim 1 , or combination thereof.14. The compound of claim 13 , further comprising ...

Подробнее
Номер записи: 27
03-10-2013 дата публикации

PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES

Номер: US20130261178A1
Автор: Baker Jillian Glenda, Daras Etienne, Fischer Peter Martin, Fromont Christophe, Hill Stephen John, Jadhav Gopal, Kellam Barrie, Mistry Shailesh
Принадлежит:

A compound of formula I-0, and its pharmaceutically acceptable salt or salts and physiologically hydrolysable derivatives in free form or salt form: 2. The compound as claimed in wherein Ris selected from unsubstituted and substituted Ccycloalkyl claim 1 , Ccycloalkyl-Calkyl claim 1 , Calkyl claim 1 , Caryl-Calkyl claim 1 , Calkoxy-Caryl-Calkyl.3. The compound as claimed in wherein Xis selected from CO claim 1 , CS claim 1 , SOand a single bond.4. The compound as claimed in wherein Rand Rare selected from ROZO as hereinbefore defined claim 1 , m- claim 1 ,p-(OCH)or o- claim 1 , m- or p-OH claim 1 , F claim 1 , Cl claim 1 , Br claim 1 , NH claim 1 , R claim 1 , OR claim 1 , or CFor a combination thereof.12. A process for the preparation of a compound of formula I-0 or subformulae as defined in .14. A composition comprising a therapeutically effective amount of a compound of formula I-0 or subformulae or its pharmaceutically acceptable salt and physiologically hydrolysable derivative as defined in in association with one or more pharmaceutical carriers or diluents.15. The use of a compound of formula I-0 or subformulae or pharmaceutically acceptable salt or composition as defined in in the prevention or treatment of a condition selected from ischaemic heart disease claim 1 , hypertension and heart failure claim 1 , more preferably with concomitant respiratory disease claim 1 , in particular asthma or COPD.16. A method of treating a condition selected from ischaemic heart disease (also known as myocardial infarction or angina) claim 1 , hypertension and heart failure claim 1 , restenosis and cardiomyopathy claim 1 , more preferably with concomitant respiratory disease claim 1 , in particular asthma or COPD claim 1 , said method comprising administering to a subject in need thereof claim 1 , a compound of formula I-0 or subformulae or pharmaceutically acceptable salt or composition thereof as defined in in an amount sufficient to treat the condition.17. A method of ...

Подробнее
Номер записи: 28
17-10-2013 дата публикации

NOVEL ANTI-INFLAMMATORY METABOLITE DERIVED FROM OMEGA-3-TYPE FATTY ACID

Номер: US20130274327A1
Автор: Arai Hiroyuki, ARITA Makoto, Isobe Yosuke, Kubota Tadafumi
Принадлежит:

The purpose is to provide a compound which can overcomes the disadvantages of conventional steroid drugs and NSAID. It is found that specific epoxy monohydroxy forms of eicosapentaenoic acid, docosahexaenoic acid and docosapentaenoic acid which are independently represented by formulae [chemical formula 1], [chemical formula 5] and the like have an inhibitory activity on neutrophils. This compound can inhibit the invasion of neutrophils into tissues and the activation of neutrophils which are observed in acute inflammations. 3. A neutrophil suppressant comprising the compound according to claim 1 , solvate of the compound claim 1 , pharmaceutically acceptable salt of the compound claim 1 , or solvate of the salt.4. A drug comprising the compound according to claim 1 , solvate of the compound claim 1 , pharmaceutically acceptable salt of the compound claim 1 , or solvate of the salt.5. The drug according to claim 4 , wherein the drug is used for the treatment or prevention of a condition claim 4 , disorder claim 4 , or state selected from pulmonary conditions selected from pulmonary distress syndrome claim 4 , adult respiratory distress syndrome claim 4 , and chronic obstructive pulmonary disease (COPD); ischemic conditions selected from ischemic heart disease claim 4 , ischemic kidney disease claim 4 , ischemic brain disease claim 4 , and ischemic liver disease; inflammatory conditions; and stress-related conditions selected from erosive gastritis claim 4 , gastric ulcer claim 4 , duodenal ulcer claim 4 , bronchial asthma claim 4 , ulcerative colitis claim 4 , arteriosclerosis claim 4 , Crohn's disease claim 4 , malignant tumor claim 4 , ovarian cyst claim 4 , salpingitis claim 4 , uterine myoma claim 4 , endometriosis claim 4 , spontaneous abortion claim 4 , toxemia of pregnancy claim 4 , infertility claim 4 , and dysmenorrhea.6. A method for producing the compound according to or claim 4 , solvate of the compound claim 4 , pharmaceutically acceptable salt of the ...

Подробнее
Номер записи: 29
24-10-2013 дата публикации

BRANCHED SILOXANES AND METHODS FOR SYNTHESIS

Номер: US20130281713A1
Автор: Jacobsson MIchael B., OGAWA Tsuyoshi, Willson Grant
Принадлежит: BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM

The present invention describes branched and functionalized siloxanes and methods for making such compounds. The compounds have a variety of uses. One preferred application is as novel planarizing material for lithography, in which case functionalized branched siloxane, such as an epoxy-modified branched siloxane is particularly useful. 2. The method of claim 1 , wherein said siloxane comprising a silicon-hydrogen bond represented by the formula (a) is 3H claim 1 ,5H-octamethyltetrasiloxane.3. The method of claim 1 , wherein m is either 2 or 3.4. The method of claim 2 , wherein said 3H claim 2 ,5H-octamethyltetrasiloxane claim 2 , prior to reacting with said asymmetric linear siloxane claim 2 , is exposed to a catalyst in the presence of water.5. The method of claim 4 , wherein said catalyst is removed prior to reacting said 3H claim 4 ,5H-octamethyltetrasiloxane with said asymmetric linear siloxane.6. The method of claim 4 , wherein said catalyst is a palladium catalyst.7. The method of claim 1 , wherein the halogen of said asymmetric linear siloxane is chlorine.8. The method of claim 1 , further comprising the step of purifying the branched siloxane by distillation claim 1 , so as to remove said byproducts of the synthesis reaction and provide a purified branched siloxane.9. The method of claim 8 , further comprising the step of functionalizing said purified branched siloxane.10. The method of claim 9 , wherein said functionalizing comprises attaching photo-crosslinkable moieties claim 9 , said moieties selected from the group consisting of acrylates claim 9 , methacrylates claim 9 , vinyls and epoxides.11. The method of claim 9 , wherein said functionalizing comprises hydrosylilation.12. The branched siloxane Si-12 having the structure shown in .13. The functionalized branched siloxane Si-12 having the structure shown in claim 9 , wherein X is a chemical moiety.14. The functionalized branched siloxane Epoxy-Si-12 having the structure shown in . The present ...

Подробнее
Номер записи: 30
24-10-2013 дата публикации

Process for producing olefin oxide

Номер: US20130281722A1
Автор: Anusorn Seubsai, Selim Senkan, Yoshihiko Ohishi
Принадлежит: Sumitomo Chemical Co Ltd

A process for producing an olefin oxide which comprises reacting an olefin with oxygen in the presence of a catalyst comprising a copper oxide and a tellurium oxide.

Подробнее
Номер записи: 31
31-10-2013 дата публикации

EPOXY RESIN, EPOXY RESIN COMPOUND COMPRISING THE SAME, AND RADIANT HEAT CIRCUIT BOARD USING THE COMPOUND

Номер: US20130284502A1
Автор: Cho In Hee, JEONG Jaehun, Kim Hae Yeon, Lee Hyuk Soo, MOON Sungbae, Park Jae Man, PARK Jeungook, YOON JongHeum, YUN Sungjin
Принадлежит: LG INNOTEK CO., LTD.

An epoxy resin compound including an epoxy resin, a hardening agent, and an inorganic filler as a main component is provided. The epoxy resin includes an epoxy resin represented by a chemical formula. Therefore, the epoxy resin having a mesogen structure that increases crystallinity is used, and thus thermal conductivity can be increased. Further, the epoxy resin is used as an insulating material for a printed circuit board, and thus a high radiant heat substrate can be provided. 4. The epoxy resin compound of claim 1 , wherein the inorganic filler is included in 40 wt % to 97 wt % with respect to a total weight of the epoxy resin compound.5. The epoxy resin compound of claim 1 , wherein the inorganic filler includes at least one of alumina claim 1 , boron nitride claim 1 , aluminum nitride claim 1 , crystalline silica and silicon nitride.6. The epoxy resin compound of claim 1 , wherein the epoxy resin is included in 3 wt % to 60 wt % with respect to a total weight of the epoxy resin compound.7. The epoxy resin compound of claim 1 , wherein the epoxy resin further comprises at least one non-crystalline epoxy resin.9. The epoxy resin compound of claim 1 , wherein the epoxy resin represented by Chemical Formula 1 is included in 12 wt % or more with respect to the whole epoxy resin.10. A radiant heat circuit board comprising:a metal plate;an insulating layer formed on the metal plate; anda circuit pattern formed on the insulating layer,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'wherein the insulating layer is formed by hardening the epoxy resin compound of .'}11. The radiant heat circuit board of claim 10 , wherein the inorganic filler is included in 40 wt % to 97 wt % with respect to a total weight of the epoxy resin compound.12. The radiant heat circuit board of claim 11 , wherein the inorganic filler includes at least one of alumina claim 11 , boron nitride claim 11 , aluminum nitride claim 11 , crystalline silica and silicon nitride.13. The radiant heat ...

Подробнее
Номер записи: 32
21-11-2013 дата публикации

O-NITRO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME

Номер: US20130309324A1
Автор: Bednarski Mark D., Cannizzo Louis F., Knox Susan, Ning Shoucheng, Velarde Stephen P., Wardle Robert B., Warner Kristin F.
Принадлежит:

The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease. 3. The compound of claim 2 , wherein X is —O—.5. The compound of claim 4 , wherein X is —O—.7. The pharmaceutical composition of claim 6 , further comprising at least one other therapeutic agent.8. The pharmaceutical composition of claim 6 , further comprising at least one chemotherapeutic agent.9. The pharmaceutical composition of claim 6 , further comprising cis-platin.10. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition comprises a therapeutically effective amount of the at least one O-nitro compound or the pharmaceutically acceptable salt claim 6 , hydrate claim 6 , or solvate thereof.11. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition comprises from about 0.001 mg to about 100 mg of the at least one O-nitro compound or the pharmaceutically acceptable salt claim 6 , hydrate claim 6 , or solvate thereof per kg body weight This application is a continuation of U.S. patent application Ser. No. 13/484,138, filed May 30, 2012, pending, which application is a divisional of U.S. patent application Ser. No. 11/502,974, filed Aug. 11, 2006, now abandoned, which application claims priority to U.S. Provisional Application Ser. No. 60/707,896, filed Aug. 12, 2005, each of which is hereby incorporated herein by this reference in its entirety.The present invention relates generally to pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and pharmaceutical compositions thereof to treat or prevent diseases characterized by abnormal cell proliferation such as cancer.Abnormal cell proliferation is a characteristic symptom of cancer. ...

Подробнее
Номер записи: 33
21-11-2013 дата публикации

TRICYCLIC LACTONES FOR TREATMENT OF CANCER

Номер: US20130310451A1
Автор: Gidlöf Ritha, Johansson Martin, MUNOZ EDUARDO, Sterner Olov
Принадлежит: Glactone Pharma Development AB

The present invention discloses novel compounds useful for the inhibition of IL-6/STAT signaling and/or PI3K/NF-κB signaling in the treatment of associated diseases or conditions, e.g. cancer. A pharmaceutical composition comprising such novel compounds, its use and a method thereof, is also disclosed. 3. A compound according to claim 1 , wherein R claim 1 , R′ claim 1 , R claim 1 , R′ claim 1 , R claim 1 , R′ claim 1 , Rand R′ are independently selected from the group consisting of H claim 1 , C1-5 alkyl claim 1 , aryl claim 1 , CH2aryl claim 1 , heteroaryl and CH2heteroaryl.4. (canceled)5. A compound according to claim 3 , wherein at least one of R claim 3 , R′ claim 3 , R claim 3 , R′ claim 3 , Rand R′ is selected from the group consisting of C1-5 alkyl claim 3 , aryl claim 3 , CH2aryl claim 3 , heteroaryl and CH2heteroaryl.6. A compound according to claim 5 , wherein at least one of R claim 5 , R′ claim 5 , Rand R′ is selected from the group consisting of C1-5 alkyl claim 5 , aryl claim 5 , CH2aryl claim 5 , heteroaryl and CH2heteroaryl.7. A compound according to claim 6 , wherein at least one of Rand R′ is selected from the group consisting of C1-5 alkyl claim 6 , aryl claim 6 , CH2aryl claim 6 , heteroaryl and CH2heteroaryl.8. (canceled)9. A compound according to claim 1 , wherein Rand R′ are independently selected from the group consisting of H and methyl.10. A compound according to claim 1 , wherein said compound is a compound according to formula (II) and Ris C1-5 alkyl or wherein said compound is a compound according to formula (I) and Ris OH claim 1 , OC1-5 claim 1 , OC1-5 fluoroalkyl claim 1 , or OC(O)C1-5 alkyl.11. A compound according to claim 1 , wherein R claim 1 , R′ claim 1 , R claim 1 , R′ R claim 1 , R′ claim 1 , Rand R′ are independently selected from the group consisting of H claim 1 , C1-5 alkyl claim 1 , aryl claim 1 , CH2aryl claim 1 , heteroaryl and CH2heteroaryl;{'sub': '5', 'R, if present, is OH, NHC0-5 alkyl, NHaryl or NHheteroaryl; and ...

Подробнее
Номер записи: 34
28-11-2013 дата публикации

COPOLYMERIZABLE SURFACTANTS

Номер: US20130317190A1
Автор: Busch Stefan, Held Uwe, Klagge Ronald, Mausberg Thomas, Scherer Markus, Schliwka Thomas
Принадлежит: Cognis IP Management GmbH

The invention relates to the use of compounds of the formula (I), R—CH(O—(AO)X)—CH—O—(AO)—CH—CH═CH, where: R denotes an alkyl radical which has 8 to 18 carbon atoms and can be saturated or unsaturated, straight-chain or branched; X denotes a sulfate or phosphate group or hydrogen; (AO) denotes an alkylene oxide unit, selected from the group consisting of ethylene oxide, propylene oxide or butylene oxide; n denotes a number in the range of 0 to 50; and m denotes zero or a number in the range of 1 to 30; as copolymerizable emulsifiers in the emulsion polymerization of olefinically unsaturated monomers. 3. The method of claim 2 , wherein X is a sulfate or phosphate group.4. The method of claim 3 , wherein the sulfate or phosphate group is in partly or wholly neutralized form.5. The method of claim 2 , wherein the degree of alkoxylation n is from 1 to 30.6. The method of claim 5 , wherein the degree of alkoxylation n is from 3 to 10 and (AO) is an ethylene oxide unit.7. A process for preparing a polymer by emulsion polymerization of an olefinically unsaturated monomer claim 1 , which process comprises utilizing said compound (I) according to as a copolymerizable emulsifier.8. The compound of claim 1 , wherein X is a sulfate or phosphate group.9. The compound of claim 8 , wherein the sulfate or phosphate group is in partly or wholly neutralized form.10. The compound of claim 1 , wherein the degree of alkoxylation n is from 1 to 30.11. The compound of claim 10 , wherein the degree of alkoxylation n is from 3 to 10 and (AO) is an ethylene oxide unit.12. The method of claim 2 , wherein the compound of formula (I) is copolymerized in the polymer.13. The method of claim 2 , further comprising initiating the reaction with potassium peroxodisulfate or a redox initiator.14. The method of claim 2 , wherein the compound of formula (I) is in salt form. The present invention lies within the polymer sector and relates to allyl ethers with a specific structure and also to their use as ...

Подробнее
Номер записи: 35
26-12-2013 дата публикации

HONOKIOL ANALOGS AND THEIR USE IN TREATING CANCERS

Номер: US20130345302A1
Автор: Arbiser Jack L.
Принадлежит:

Compounds, pharmaceutical compositions including the compounds, and methods of preparation and use thereof are disclosed. The compounds are honokiol analogs. The compounds and compositions can be used to treat and/or prevent a wide variety of cancers, including drug resistant cancers. Representative honokiol analogs include diepoxide honokiol analogues. The compounds are believed to function, at least, by inhibiting angiogenesis and/or inducing apoptosis. Thus, the compounds are novel therapeutic agents for a variety of cancers. 1. A compound selected from the group consisting of valproate mono and diesters of honokiol , dichloroacetate mono and diesters of honokiol , and Calkyl phosphate mono and di-esters of honokiol.3. A compound of claim 1 , wherein both of X are O.4. A compound of claim 1 , wherein one of X is O claim 1 , and the other represents a bond between the two carbons to which it is attached.5. A compound of claim 1 , wherein all Y are C bonded to H or a substituent claim 1 , G.6. A compound of claim 1 , wherein each Ris H.7. A compound of claim 1 , wherein each W is CH.8. A compound of claim 1 , wherein two of Rrepresent a dichloroacetate.9. A method for treating a cancer in a mammal claim 1 , comprising administering to the mammal a therapeutically effective amount of a compound of in an amount sufficient to induce apoptosis and/or inhibit angiogenesis claim 1 , such that the growth of the tumor is at least partially inhibited.10. The method of wherein the cancer is selected from a group consisting of hemangioma claim 9 , melanoma claim 9 , rectal carcinoma claim 9 , colon carcinoma claim 9 , breast carcinoma claim 9 , ovarian carcinoma claim 9 , small cell lung carcinoma claim 9 , colon carcinoma claim 9 , chronic lymphocytic carcinoma claim 9 , hairy cell leukemia claim 9 , osophogeal carcinoma claim 9 , prostate carcinoma claim 9 , breast cancer claim 9 , myeloma claim 9 , and lymphoma.11. The method of claim 10 , wherein the cancer is a ...

Подробнее
Номер записи: 36
02-01-2014 дата публикации

NOVEL COMPOUND HAVING alpha-CYANOACRYLATE STRUCTURE, DYE, AND COLORED PHOTOSENSITIVE COMPOSITION

Номер: US20140005292A1
Автор: Koich Shigeno, Masaaki Shimizu, Yosuke Maeda
Принадлежит: Adeka Corp

A compound represented by the following general formula (1). In the formula, A represents a benzene ring, a naphthalene ring and the like, wherein these rings may be substituted with a halogen atom and the like, R 1 represents a hydrogen atom and the like, R 2 represents a C 1-35 hydrocarbon group having or not having at least one group selected from an epoxy group, 4-vinylphenyl group and a (meth)acryloyloxy group, or a hydrogen atom, wherein at least one of R 2 with n occurrences is a C 3-35 hydrocarbon group having at least one group selected from an epoxy group, a 4-vinylphenyl group and a (meth)acryloyloxy group, n represents an integer of 1 to 6, and X represents a nitrogen atom, an oxygen atom, a sulfur atom, a phosphorus atom, or an n-valent organic group having 35 or less carbon atoms.

Подробнее
Номер записи: 37
06-03-2014 дата публикации

ANTIOXIDANT INFLAMMATION MODULATORS: C-17 HOMOLOGATED OLEANOLIC ACID DERIVATIVES

Номер: US20140066408A1
Автор: GREINER Jack, Jiang Xin, LIU Xiaofeng, SZUCS Stephen S., Visnick Melean
Принадлежит: REATA PHARMACEUTICALS, INC.

This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: 614-. (canceled)15. The compound of claim 5 , wherein Y is alkanediylor substituted alkanediyl.1618-. (canceled)19. The compound of claim 5 , wherein Xis ORand Ris absent.20. The compound of claim 4 , wherein Xis hydrogen.21. The compound of claim 5 , wherein Ris —OH.2228-. (canceled)29. The compound of claim 5 , wherein Ris acylor substituted acyl.30. The compound of claim 29 , wherein Ris selected from the group consisting of —C(═O)OH claim 29 , —C(═O)OCH claim 29 , —C(═O)NHCH claim 29 , —C(═O)NHCHCH claim 29 , and —C(═O)NHCHCF.31. The compound of claim 5 , wherein Ris acyloxyor substituted acyloxy.3246-. (canceled)47. The compound of claim 5 , wherein Ris —CN.4850-. (canceled)51. The compound of claim 3 , wherein Ris absent.5253-. (canceled)54. The compound of claim 2 , wherein Rand Rare each methyl.55. The compound of claim 2 , wherein Rand Rare each hydrogen.56. The compound of claim 1 , wherein Rand Rare each hydrogen.57. The compound of claim 1 , wherein Rand Rare each methyl.58. (canceled)59. The compound of claim 5 , wherein the bond between carbons 9 and 11 is a single bond.60. The compound of claim 5 , wherein the bond between carbons 9 and 11 is a double bond.61137-. (canceled)138. A pharmaceutical composition comprising as an active ingredient a compound of and a pharmaceutically acceptable carrier.139146-. (canceled)147. A therapeutic method comprising administering a pharmaceutically effective amount of a compound of to a subject.148. The method of claim 147 , wherein the subject is a human.149. (canceled)150. A method of treating cancer in a subject claim 5 , comprising administering to the subject a pharmaceutically effective amount of a compound of .151173-. (canceled)174. A method of treating or preventing a disease with an inflammatory component in a subject claim 5 , comprising administering to the subject a pharmaceutically effective amount of a ...

Подробнее
Номер записи: 38
06-03-2014 дата публикации

METHOD OF SYNTHESIS OF SUBSTITUTED HEXITOLS SUCH AS DIANHYDROGALACTITOL

Номер: US20140066642A1
Автор: Brown Dennis M., Li Mike Tso-Ping
Принадлежит: Del Mar Pharmaceuticals

The present invention provides an efficient method of synthesizing and purifying dianhydrohexitols such as dianhydrogalactitol. In general, as applied to dianhydrogalactitol, the method comprises: (1) reacting dulcitol with a concentrated solution of hydrobromic acid at a temperature of about 80° C. to produce dibromogalactitol; (2) reacting the dibromogalactitol with potassium carbonate in t-butanol to produce dianhydrogalactitol; and (3) purifying the dianhydrogalactitol using a slurry of ethyl ether to produce purified dianhydrogalactitol. Another method produces dianhydrogalactitol from dulcitol; this method comprises: (1) reacting dulcitol with a reactant to convert the 1,6-hydroxy groups of dulcitol to an effective leaving group to generate an intermediate; and (2) reacting the intermediate with an inorganic weak base to produce dianhydrogalactitol through an intramolecular S2 reaction. Other methods for the synthesis of dianhydrogalactitol from dulcitol are described. 1. A method for synthesizing and recrystallizing a dianhydrohexitol comprising the steps of:(a) converting a hexahydroxyl-substituted sugar alcohol to a dibromo derivative of the hexahydroxyl-substituted sugar alcohol by reaction of the dulcitol with hydrobromic acid for from about 18 hours to about 36 hours at an elevated temperature;(b) adding the product of step (a) to water, agitating the product of step (a) added to water for from about 18 hours to about 36 hours, filtering the mixture of the product of step (a) and water, washing the mixture with a large volume of water, drying the solid product under nitrogen, and then subsequently washing the dried solid product with a large volume of an aliphatic ether;(c) reacting the product of step (b) with a carbonate of an alkali metal in a polar aprotic solvent at an elevated temperature;(d) filtering the product of step (c) to remove the solids;(e) washing the solids removed in step (d) with a polar aprotic solvent and combining the washings with ...

Подробнее
Номер записи: 39
04-01-2018 дата публикации

METHODS FOR INHIBITING CONVERSION OF CHOLINE TO TRIMETHYLAMINE (TMA)

Номер: US20180000754A1
Автор: CODY David Blair, GARCIA-GARCIA Jose Carlos, GERBERICK George Franklin, Gu Xiaodong, Hazen Stanley Leon, REED Jodie Michelle, Reilly Michael, SIVIK Mark Robert, Wos John August
Принадлежит:

A method of inhibiting the conversion of choline to trimethylamine (TMA) and lowering TMAO by providing a composition comprising a compound set forth in Formula (I): 2. The composition of wherein the compound is selected from the group consisting of: 2-(methoxycarbonyl)-N claim 1 ,N-dimethyl-N-(prop-2-yn-1-yl)prop-2-en-1-aminium bromide claim 1 , 2-carboxy-N claim 1 ,N-dimethyl-N-(prop-2-yn-1-yl)prop-2-en-1-aminium bromide claim 1 , 2-cyano-N-(2-hydroxyethyl)-N claim 1 ,N-dimethylprop-2-en-1-aminium bromide claim 1 , 2-cyano-N claim 1 ,N-dimethyl-N-(prop-2-yn-1-yl)prop-2-en-1-aminium bromide claim 1 , or N-(3-methoxy-2 claim 1 ,3-dioxopropyl)-N claim 1 ,N-dimethylprop-2-yn-1-aminium bromide.3. The composition of wherein{'sub': '12', 'Ris acrylic, acetal, alkoxy, amido, amino, carboxylic, carboxylate, or glyoxyl,'}{'sub': 13', '14', '1', '4, 'Rand Rare independently selected from C-Calkyl; and'}{'sub': '15', 'Ris propargyl'}6. The method of wherein the compound is selected from the group consisting of: 2-(methoxycarbonyl)-N claim 4 ,N-dimethyl-N-(prop-2-yn-1-yl)prop-2-en-1-aminium claim 4 , 4-carboxy-N claim 4 ,N-dimethyl-N-(prop-2-yn-1-yl)butan-1-aminium claim 4 , N-(2 claim 4 ,2-dimethoxyethyl)-N claim 4 ,N-dimethylprop-2-yn-1-aminium claim 4 , N-(2 claim 4 ,2-dihydroxyethyl)-N claim 4 ,N-dimethylprop-2-yn-1-aminium claim 4 , N-(2-hydroxyethyl)-N claim 4 ,N-dimethylbut-3-yn-1-aminium claim 4 , N-(2 claim 4 ,2-diethoxyethyl)-N claim 4 ,N-dimethylprop-2-yn-1-aminium claim 4 , 4-hydroxy-1-methyl-1-(prop-2-yn-1-yl)piperidin-1-ium claim 4 , 2-cyano-N claim 4 ,N-dimethyl-N-(prop-2-yn-1-yl)prop-2-en-1-aminium claim 4 , N-(carboxymethyl)-N claim 4 ,N-dimethylprop-2-yn-1-aminium claim 4 , trimethyl(prop-2-ynyl)ammonium claim 4 , allyl-(cyanomethyl)-dimethyl-ammonium claim 4 , or N-(2-hydroxyethyl)-N claim 4 ,N-dimethylprop-2-yn-1-aminium and a pharmaceutically acceptable salt thereof.9. The method of further comprising administering to the individual a second agent selected ...

Подробнее
Номер записи: 40
02-01-2020 дата публикации

METHODS FOR CONDITIONING AN ETHYLENE EPOXIDATION CATALYST AND ASSOCIATED METHODS FOR THE PRODUCTION OF ETHYLENE OXIDE

Номер: US20200001277A1
Автор: LOCKEMEYER John Robert, MATUSZ Marek, PADDOCK Robert Lewis, Yeates Randall Clayton
Принадлежит:

Methods for conditioning an ethylene epoxidation catalyst are provided. The conditioning methods comprise contacting an ethylene epoxidation catalyst comprising a carrier, having silver and a rhenium promoter deposited thereon, with a conditioning feed gas comprising oxygen for a period of time of at least 2 hours at a temperature that is above 180° C. and at most 250° C., wherein the contacting of the ethylene epoxidation catalyst with the conditioning feed gas occurs in an epoxidation reactor and in the absence of ethylene. Associated methods for the epoxidation of ethylene are also provided. 1. A method for the conditioning of an ethylene epoxidation catalyst comprising:contacting an ethylene epoxidation catalyst comprising a carrier, having silver and a rhenium promoter deposited thereon, with a conditioning feed gas comprising oxygen for a period of time of at least 2 hours at a temperature that is above 180° C. and at most 250° C., wherein the contacting of the ethylene epoxidation catalyst with the conditioning feed gas occurs in an epoxidation reactor and in the absence of ethylene.2. The method of wherein the conditioning gas further comprises an inert gas and an organic chloride.3. The method of wherein the temperature is from at least 185° C. to at most 250° C.4. The method of wherein the temperature is from at least 185° C. to at most 245° C.5. The method of wherein the conditioning feed gas comprises oxygen in a concentration of from 0.5 to 21 mole-% claim 1 , relative to the total conditioning feed gas.6. The method of wherein the period of time is from 2 hours to 200 hours.7. The method of wherein the period of time is from 2 hours to 72 hours.8. The method of further comprising contacting the ethylene epoxidation catalyst with a sweeping gas.9. A method for the epoxidation of ethylene comprising:contacting an ethylene epoxidation catalyst comprising a carrier, having silver and a rhenium promoter deposited thereon, with a conditioning feed gas ...

Подробнее
Номер записи: 41
04-01-2018 дата публикации

EPOXY COMPOUND, METHOD FOR PRODUCING THE SAME, EPOXY RESIN COMPOSITION, AND CURED PRODUCT THEREOF

Номер: US20180002261A1
Автор: Hayashi Masamichi, Kinoshita Hiroshi, Morinaga Kunihiro, Yoshimoto Yasuyo
Принадлежит:

The present invention provides an epoxy compound which is 2,2′,7,7′-tetraglycidyloxy-1,1′-binaphthalene. Also, the present invention provides a method for producing [1,1′-binaphthalene]-2,2′,7,7′-tetraol, the method including a step of bringing a crude product produced by dimerization reaction of naphthalene-2,7-diol or a naphthalene-2,7-diol derivative into contact with an aromatic solvent; a step of separating [1,1′-binaphthalene]-2,2′,7,7′-tetraol dissolved in the aromatic solvent from insoluble substances; and a step of removing the solvent from a solution of [1,1′-binaphthalene]-2,2′,7,7′-tetraol. The present invention also provides a method for producing an epoxy compound, the method including reacting [1,1′-binaphthalene]-2,2′,7,7′-tetraol or [1,1′-binaphthalene]-2,2′,7,7′-tetraol monohydrate with epihalohydrin. 1. An epoxy compound which is 2 ,2′ ,7 ,7′-tetraglycidyloxy-1 ,1′-binaphthalene.2. A method for producing an epoxy compound , the method comprising reacting [1 ,1′-binaphthalene]-2 ,2′ ,7 ,7′-tetraol or [1 ,1′-binaphthalene]-2 ,2′ ,7 ,7′-tetraol monohydrate with epihalohydrin.3. An epoxy compound produced by the method according to .4. An epoxy resin composition comprising the epoxy compound according to and a curing agent.5. A cured product produced by curing the epoxy resin composition according to .611.-. (canceled)12. An epoxy resin composition comprising the epoxy compound according to and a curing agent.13. A cured product produced by curing the epoxy resin composition according to . This application is a divisional application of U.S. Ser. No. 14/431,968 filed on Mar. 27, 2015, which claims the right of priority under 35 U.S.C. §119 based on Japanese Patent Application Nos. 2012-261035 filed on Nov. 29, 2012 and 2012-216516 filed on Sep. 28, 2012. The entire contents of these applications are incorporated herein by reference in their entirety.The present invention relates to an epoxy compound and a method for producing the compound which ...

Подробнее
Номер записи: 42
02-01-2020 дата публикации

METHODS OF SYNTHESIZING A PROSTACYCLIN ANALOG

Номер: US20200002261A1
Автор: Chambournier Gilles, Endres Gregory William, Fedij Victor, Hering Kirk William, II Thomas James, Krell, MAHMOUD Hussien Mahmoud
Принадлежит: CAYMAN CHEMICAL COMPANY INCORPORATED

The present invention provides processes for preparing a prostacyclin analogue of Formula I 4. The method of claim 3 , wherein the transition metal catalyst comprises a compound or complex either of which comprises copper having a +1 oxidation state.5. The method of claim 4 , wherein the transition metal catalyst comprises CuI.15. The method of claim 14 , further comprising the step of:xxiv) reacting the compound of Formula I with diethanolamine in the presence of an organic solvent to generate the diethanolamine salt of the compound of Formula I.18. The method of claim 17 , wherein the derivatizing reagent comprises 3 claim 17 ,5-dinitrobenzoyl chloride and the alcohol comprises methanol.20. The method of claim 19 , further comprising the step:xlii) recrystallizing the precipitate of step xli). This application is a divisional application of U.S. patent application Ser. No. 15/874,093, filed Jan. 18, 2018, which is a divisional application of U.S. patent application Ser. No. 15/583,457, filed May 1, 2017, now U.S. Pat. No. 9,908,834, issued Mar. 6, 2018, which is a divisional application of U.S. patent application Ser. No. 14/650,234, filed Jun. 5, 2015, which is a 35 U.S.C. § 371 United States National Phase Application of PCT Application Serial No. PCT/US2013/073474, filed Dec. 6, 2013, which claims the benefit of and priority to U.S. provisional application Ser. No. 61/734,672, filed Dec. 7, 2012, and 61/777,882, filed Mar. 12, 2013. The entire contents of the aforementioned disclosures are incorporated herein by reference in their entireties.The present invention relates to processes and intermediates for the preparation of prostacyclin analog that are useful for treating hypertension and other diseases.Prostacyclin derivatives and analogs are useful pharmaceutical compounds possessing activities such as platelet aggregation inhibition, gastric secretion reduction, lesion inhibition, vasodilation, and bronchodilation.Treprostinil is a synthetic prostacyclin ...

Подробнее
Номер записи: 43
05-01-2017 дата публикации

DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS

Номер: US20170002003A1
Автор: Bischoff Matthias, Hausch Felix, Pomplun Sebastian, Wang Yansong
Принадлежит: Max-Planck-Gesellschaft zur Forderung der Wissensc haften e.V.

The present invention relates to diazabicyclo[4.3.1]decane derivatives, pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said diazabicyclo[4.3.1]decane derivatives can be used for prophylaxis and/or treatment of psychiatric disorders and neurodegenerative diseases, disorders and conditions. 4. Compound according to selected from the group consisting of:(1S,5S,6R)-5-acetyl-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,2-((1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decan-5-yl)acetaldehyde,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(2-hydroxypropan-2-yl)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-((R)-1-hydroxyethyl)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-((S)-1-hydroxyethyl)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(2-hydroxyethyl)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decane-5-carbaldehyde,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decane-5-carboxylic acid,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-2-oxo-3,10-diazabicyclo[4.3.1]decane-5-carboxamide,(1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-5-((methylamino)methyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-(hydroxymethyl)-3-(2-methoxyethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5R,6R)-10-((3,5-dichlorophenyl)sulfonyl)-3-(2-methoxyethyl)-5-(methoxymethyl)-3,10-diazabicyclo[4.3.1]decan-2-one,(1S,5S,6R)-10-((3,5-dichlorophenyl)sulfonyl)-5-ethyl-3-(2- ...

Подробнее
Номер записи: 44
07-01-2016 дата публикации

DIENE/DIENOPHILE COUPLES AND THERMOSETTING RESIN COMPOSITIONS HAVING REWORKABILITY

Номер: US20160002510A1
Автор: CHAMPAGNE Timothy M., Israel Jonathan B., Jordan Benny E., Klemarczyk Philip T., Sridhar Laxmisha M., Zhang XianMan
Принадлежит:

Thermosetting resin compositions are provided that are useful for mounting onto a circuit board semiconductor devices, such as chip size or chip scale packages (“CSPs”), ball grid arrays (“BGAs”), land grid arrays (“LGAs”) and the like (collectively, “subcomponents”), or semiconductor chips. Reaction products of the compositions are controllably reworkable when subjected to appropriate conditions. 1. A curable composition reaction products of which are controllably degradable upon exposure to a temperature condition greater than a temperature condition used to cure the composition , comprising:(a) a curable resin component;(b) a curative and(c) a diene/dienophile couple functionalized with at least two carboxylic acid groups.2. An electronic device comprising a semiconductor device and a circuit board to which said semiconductor device is electrically connected or a semiconductor chip and a circuit board to which said semiconductor chip is electrically connected claim 1 , assembled using a curable composition according to as an underfill sealant between the semiconductor device and the circuit board or the semiconductor chip and the circuit board claim 1 , respectively claim 1 , wherein reaction products of the composition are capable of softening and losing their adhesiveness under exposure to temperature conditions in excess of those used to cure the composition.3. A method of sealing underfilling between a semiconductor device including a semiconductor chip mounted on a carrier substrate and a circuit board to which said semiconductor device is electrically connected or a semiconductor chip and a circuit board to which said semiconductor chip is electrically connected claim 1 , the steps of which comprise:{'claim-ref': {'@idref': 'CLM-00001', 'claims 1'}, '(a) dispensing into the underfilling between the semiconductor device and the circuit board or the semiconductor chip and the circuit board a composition according to ; and'}(b) exposing the composition as so ...

Подробнее
Номер записи: 45
07-01-2021 дата публикации

Plasticizer composition and resin composition including the same

Номер: US20210002204A1
Автор: Hyun Kyu Kim, Jeong Ju Moon, Joo Ho Kim, Seok Ho Jeong, Yun Ki Cho
Принадлежит: LG Chem Ltd

Provided is a plasticizer composition, comprising: a cyclohexane-1,4-diester-based substance of the following Chemical Formula 1; an epoxidized alkyl ester composition comprising one or more compounds of the following Chemical Formula 2; and a citrate-based substance of the following Chemical Formula 3: wherein in Chemical Formula 1 to Chemical Formula 3: R 1 and R 2 each independently are a C8 alkyl group; R 3 is a C8 to C20 alkyl group comprising one or more epoxy groups; and R 4 to R 7 each independently are a C4 to C10 alkyl group.

Подробнее
Номер записи: 46
07-01-2021 дата публикации

Propene recovery by scrubbing with a solvent/water mixture

Номер: US20210002241A1
Автор: Andrei-Nicolae Parvulescu, Bernd Metzen, Christian Mueller, Daniel Urbanczyk, Dominic RIEDEL, Joaquim Henrique Teles, Markus Weber, Marvin KRAMP, Nicolai Tonio Woerz, Ulrich MUELLERE, Ulrike Wegerle
Принадлежит: BASF SE

The invention relates to a process for preparing propylene oxide, comprising (i) providing a stream comprising propene, propane, hydrogen peroxide or a source of hydrogen peroxide, water, and an organic solvent; (ii) passing the liquid feed stream provided in (i) into an epoxidation zone comprising an epoxidation catalyst comprising a titanium zeolite, and subjecting the liquid feed stream to epoxidation reaction conditions in the epoxidation zone, obtaining a reaction mixture comprising propene, propane, propylene oxide, water, and the organic solvent; (iii) removing an effluent stream from the epoxidation zone, the effluent stream comprising propene, propane, propylene oxide, water, and the organic solvent; (iv) separating propene and propane from the effluent stream by distillation, comprising subjecting the effluent stream to distillation conditions in a distillation unit, obtaining a gaseous stream (S1) which is enriched in propene and propane compared to the effluent stream subjected to distillation conditions, and a liquid bottoms stream (S2) which is enriched in propylene oxide, water and organic solvent compared to the effluent stream subjected to distillation conditions; (v) separating propane from the stream (S1) in a separation zone, comprising subjecting the stream (S1) to washing conditions in a scrubber, wherein a solvent mixture comprising organic solvent and water is added as entraining agent, obtaining a bottoms stream (S3), which comprises organic solvent, water and at least 70 weight-% of the propene comprised in (S1); and a gaseous top stream (S4), which comprises at least 5 weight-% of the propane comprised in stream (S1).

Подробнее
Номер записи: 47
02-01-2020 дата публикации

Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer

Номер: US20200002378A1
Автор: Beausoleil Anne-Marie, Hudson Ryan, Laberge Remi-Martin, Romero F. Anthony
Принадлежит:

The proteasome inhibitors of this invention include peptide-based compounds with a short linear sequence of amino acids. An oxo or thio group is attached to the N-terminal amino acid. A protein-reactive electrophilic group such as an epoxyketone, an aziridinylketone, or a beta-lactone is attached to the C-terminal amino acid. Upon contact with a proteasome complex in a target cell, the electrophilic group reacts with a functional group in or near a binding pocket or active site of the proteasome, forming a covalent bond and thereby inactivating the proteasome. These and other proteasome inhibitors can be screened for binding affinity and an ability to selectively eliminate senescent cells or cancer cells. Compounds that selectively remove senescent cells can be developed for the treatment of conditions such as osteoarthritis, ophthalmic disease, pulmonary disease, and atherosclerosis. 117.-. (canceled)1920.-. (canceled)23. The method of claim 18 , wherein Z is selected from aldehyde claim 18 , epoxyketone claim 18 , aziridinylketone claim 18 , boronate claim 18 , boronate ester and beta-lactone.25. The method of claim 18 , wherein:X is O or S;{'sup': 0', '10', '10, 'R- is R- or R-Q-;'}{'sup': 11', '11, 'Q is selected from ethylene glycol, polyethylene glycol, —C(═O)—, —NRC(═O)—, —OC(═O)—, —C(═S)—, —NRC(═S)—, —OC(═S)— and —OC(═S)—; and'}{'sup': 10', '11, 'Rand Rare independently selected from H, alkyl and substituted alkyl.'}28. The method of claim 26 , wherein:{'sup': '1', 'sub': (1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6), 'Ris selected from Calkyl, aryl-Calkyl, substituted aryl-Calkyl, cycloalkyl-Calkyl and substituted cycloalkyl-Calkyl;'}{'sup': 2', '4, 'sub': (1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6), 'Rand Rare selected from Calkyl, substituted Calkyl, Calkoxy-Calkyl, substituted Calkoxy-Calkyl, Chydroxyalkyl and substituted Chydroxyalkyl; and'}{'sup': '3', 'sub': (1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6)', '(1-6), 'Ris selected from ...

Подробнее
Номер записи: 48
02-01-2020 дата публикации

Tunable materials

Номер: US20200002549A1
Автор: Jorma Virtanen
Принадлежит: Tesla Nanocoatings Inc

A corrosion resistant material is described including a substrate, a first material including less than about 90% of an amino group or epoxy group, between about 0.05% and about 50% siloxane, between about 5% and about 80% nanoparticles, microparticles, or macroparticles, and between about 0.1% and about 5% of a first functionalized graphitic material, a second material including less than about 90% of a silyl group, between about 0.05% and about 50% siloxane, between about 5% and about 80% nanoparticles, microparticles, or macroparticles, and between about 0.1% and about 5% of a second functionalized graphitic material, and a third material including less than about 90% of an amino group or epoxy group and a silyl group, between about 0.05% and about 50% siloxane, between about 5% and about 80% nanoparticles, microparticles, or macroparticles, and between about 0.1% and about 5% of a third functionalized graphitic material.

Подробнее
Номер записи: 49
11-01-2018 дата публикации

POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF

Номер: US20180008630A1
Автор: Petersen John S.
Принадлежит:

One aspect of the invention provides polymer conjugated MetAP2 inhibitors. While not being bound by any particular theory, it is believed that coupling the MetAP2 inhibitory core via the linkers described herein provides compounds with superior efficacy to the parent small molecules and superior pharmacokinetic profiles. In one aspect of the invention, the polymer conjugated MetAP2 inhibitors are useful in methods of treating disease, comprising administering to a subject in need thereof a therapeutically effective amount of a polymer conjugated MetAP2 inhibitor. This application is a continuation application of U.S. patent application Ser. No. 15/065,513, filed Mar. 9, 2017, now allowed, which is a continuation of Ser. No. 13/696,743, filed Nov. 7, 2012, now U.S. Pat. No. 9,320,805, which is a 35 U.S.C. 371 NATL phase entry of PCT/US2011/037857, filed May 25, 2011, which claims the benefit of, and priority to, U.S. Provisional Patent Application Ser. No. 61/347,924, filed May 25, 2010.Helmut Ringsdorf provided a theoretical framework for the design of polymer conjugates of small molecule drugs over thirty years ago (See Ringsdorf, “Structure and Properties of Pharmacologically Active Polymers”, J. POLYMER SCI.: Symposium No. 51, 135-153 (1975)). While many conjugates have been synthesized and evaluated in animals, few have progressed to clinical trials and those trials have been largely disappointing. The identification of polymer drug conjugates that represent improvements over the parent small molecules remains an area of active research.Fumagillin is a small molecule which has been used as an antimicrobial and antiprotozoal agent. Its physiochemical properties and method of production are well known (See U.S. Pat. No. 2,803,586 (Peterson, et al, incorporated herein by reference) and Turner, J. R. et al, The Stereochemistry of Fumagillin, Proc. Natl. Acad. Sci. 48, 733-735 (1962)). The fermentation product, fumagillin, may be hydrolyzed to yield the alcohol ...

Подробнее
Номер записи: 50
12-01-2017 дата публикации

NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF

Номер: US20170008884A1
Автор: Arancio Ottavio, Fa Mauro, Schiefer Isaac Thomas, Thatcher Gregory R.J.
Принадлежит:

The invention provides for novel cysteine protease inhibitors and compositions comprising novel cysteine protease derivatives. The invention further provides for methods for treatment of neurodegenerative diseases comprising administration novel cysteine protease inhibitors or compositions comprising novel cysteine protease inhibitors. In some embodiments, the cysteine protease inhibitors are calpain inhibitors. 123.-. (canceled)25: The method of claim 24 , wherein the disease is Alzheimer's Disease.27: The method of claim 26 , wherein the disease is Alzheimer's Disease.29: The method of claim 28 , wherein the subject has a neurodegenerative disease.30: The method of claim 29 , wherein the neurodegenerative disease is Alzheimer's Disease.31: The method of claim 24 , wherein the compound is formulated as a pharmaceutical composition.32: The method of claim 31 , wherein the pharmaceutical composition is formulated: as a sterile injectable solution or dispersion claim 31 , for intravenous or oral administration claim 31 , or for transmucosal or transdermal administration.411: The compound of claim (a) claim 31 , wherein the compound is selected from(a) (2S,3 S)-3-((S)-1-(2,6-difluorophenylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylic acid;(2 S,3 S)-3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylic acid;(2R,3R)-3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-4-methyl-1-oxopentan-2-ylcarbamoyl)oxirane-2-carboxylic acid;(2S,3 S)-3-(1-(4-(4-fluorophenyl)thiazol-2-ylamino)-3-(1H-imidazol-4-yl)-1-oxopropan-2-ylcarbamoyl)oxirane-2-carboxylic acid;(2S,3 S)-3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid;(2S,3 S)-3-((S)-1-(4-(4-ethynylphenyl)thiazol-2-ylamino)-1-oxo-3-(thiazol-4-yl)propan-2-ylcarbamoyl)oxirane-2-carboxylic acid;(2S,3 S)-3-((S)-1-(4-(4-fluorophenyl)thiazol-2-ylamino)-3-(1-methyl-1H-imidazol-4-yl)-1-oxopropan-2-ylcarbamoyl) ...

Подробнее
Номер записи: 51
14-01-2016 дата публикации

PHENOLIC EPOXY COMPOUNDS

Номер: US20160009672A1
Автор: Adam Georgius Abidal
Принадлежит:

Disclosed herein are compositions and methods of making phenolic compounds, and resins comprising these phenolic compounds. The compounds include multifunctional epoxies, amino glycidyl derivatives, and multi-functional amines prepared from hydroxymethyl derivatives of phenols and bisphenols. 25-. (canceled)6. The compound of claim 1 , wherein:{'sub': '1', 'Ris H or Z;'}{'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris —N(Z), —N(CH—O—Z), —N(CHCH—O—Z), —N(CHOH), —N(CHNH), or —N(CHCHOH);'}{'sub': 3', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris —N(Z), —N(CH—O—Z), —N(CHCH—O—Z), —N(CHOH), —N(CHNH), or —N(CHCHOH); and'}{'sub': 4', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris —N(Z), —N(CH—O—Z), —N(CHCH—O—Z), —N(CHOH), —N(CHNH), or —N(CHCHOH).'}7. The compound of claim 1 , wherein:{'sub': '1', 'Ris Z;'}{'sub': 2', '2', '2', '2', '2', '2', '2, 'Ris —N(Z), —N(CH—O—Z), or —N(CHCH—O—Z);'}{'sub': 3', '2', '2', '2', '2', '2', '2, 'Ris —N(Z), —N(CH—O—Z), or —N(CHCH—O—Z); and'}{'sub': 4', '2', '2', '2', '2', '2', '2, 'Ris —N(Z), —N(CH—O—Z), or —N(CHCH—O—Z).'}8. The compound of claim 1 , wherein Ris Z claim 1 , Ris —N(Z) claim 1 , Ris —N(Z)and Ris —N(Z).9. The compound of claim 1 , wherein Ris Z claim 1 , and each of Ris —N(CH—O—Z) claim 1 , Ris{'sub': 2', '2', '4', '2', '2, '—N(CH—O—Z)and Ris —N(CH—O—Z).'}10. The compound of claim 1 , wherein Ris Z claim 1 , and each of Ris —N(CHCH—O—Z) claim 1 , Ris{'sub': 2', '2', '2', '4', '2', '2', '2, '—N(CHCH—O—Z)and Ris —N(CHCH—O—Z).'}11. The compound of claim 1 , wherein:{'sub': '1', 'Ris H;'}{'sub': 2', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris —N(CHOH), —N(CHNH), or —N(CHCHOH);'}{'sub': 3', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris —N(CHOH), —N(CHNH), or —N(CHCHOH); and'}{'sub': 4', '2', '2', '2', '2', '2', '2', '2', '2, 'Ris —N(CHOH), —N(CHNH), or —N(CHCHOH).'}12. The compound of claim 1 , wherein Ris H claim 1 , Ris —N(CHOH) claim 1 , Ris ...

Подробнее
Номер записи: 52
14-01-2016 дата публикации

UNSATURATED FATTY ACID ESTER-BASED COMPOSITIONS USEFUL AS PLASTIC ADDITIVES

Номер: US20160009673A1
Автор: KAZEMIZADEH Mohammad R., Maixner David E.
Принадлежит: Arkema Inc.

Compositions useful as plastic additives may be prepared from renewable resources such as vegetable oils by functionalizing an unsaturated fatty acid ester with epoxy, acyloxy, and optionally alkoxy groups. 1. A compound comprised of a fatty acid ester moiety , wherein the fatty acid ester moiety comprises at least one epoxy group and wherein the fatty acid ester moiety is substituted at least with a first substituent which is a first acyloxy group and with a second substituent which is a second acyloxy group , which may be the same as or different from the first acyloxy group , or an alkoxy group , wherein the first substituent and the second substituent are substituted on adjacent carbon atoms in the fatty acid ester moiety.2. The compound of claim 1 , wherein the fatty acid ester moiety is selected from the group consisting of fatty acid monoesters claim 1 , monoglycerides claim 1 , diglycerides claim 1 , triglycerides claim 1 , and fatty acid esters of polyols other than glycerin.3. The compound of claim 1 , wherein the first acyloxy group is a C2-C24 aliphatic acyloxy group.4. The compound of claim 1 , wherein the first acyloxy group has a structure R—C(═O)—O— claim 1 , wherein R is a straight chain claim 1 , branched or alicyclic claim 1 , saturated or unsaturated hydrocarbyl group containing one to 23 carbon atoms.5. The compound of claim 1 , wherein the first acyloxy group is an acetoxy group.6. The compound of claim 1 , wherein the second substituent is a C2-C24 aliphatic acyloxy group.7. The compound of claim 1 , wherein the second substituent has a structure R—C(═O)—O— claim 1 , wherein R is a straight chain claim 1 , branched or alicyclic claim 1 , saturated or unsaturated hydrocarbyl group containing one to 23 carbon atoms.8. The compound of claim 1 , wherein the second substituent is a C1-C24 alkoxy group.9. The compound of claim 1 , wherein the second substituent has a structure R1—O— claim 1 , wherein R1 is a straight chain claim 1 , branched or ...

Подробнее
Номер записи: 53
14-01-2016 дата публикации

Commands and method of treating cancer via RHO pathway

Номер: US20160009756A1
Автор: Weidong Xie, Xin Liu
Принадлежит: Weidong Xie

Lanosterol derivatives useful as anti-cancer agent, which can inhibit the growth of lung cancer cells, liver cancer cells, mammary cancer cells, brain cancer cells and pancreatic cancer cells, possibly by acting on the RHO pathway. These lanosterol derivatives are represented by compound LD030:

Подробнее
Номер записи: 54
14-01-2016 дата публикации

ISONONYL ESTERS BASED ON FATTY ACIDS OR FATTY ACID MIXTURES FROM TALL OIL OR LINSEED OIL

Номер: US20160009898A1
Автор: Gevers Andreas, Grass Michael, WOLDT Benjamin
Принадлежит: EVONIK DEGUSSA GmbH

The invention relates to an isononyl ester or isononyl ester mixture of an epoxidized fatty acid or an epoxidized fatty acid mixture, the fatty acid or fatty acid mixture being extracted from tall oil or linseed oil and the average number of epoxide groups per fatty acid being greater than 1.00. 1. An isononyl ester or an isononyl ester mixture of an epoxidized fatty acid or of an epoxidized fatty acid mixture ,wherein:the fatty acid or the fatty acid mixture is obtained from tall oil or linseed oil, andthe ester or the ester mixture has an average number of epoxide groups per fatty acid of greater than 1.00.2. The isononyl ester or the isononyl ester mixture of claim 1 , wherein the fatty acid or the fatty acid mixture is obtained from tall oil.3. The isononyl ester or the isononyl ester mixture of claim 1 , wherein the fatty acid or the fatty acid mixture is obtained from being linseed oil.4. The isononyl ester or the isononyl ester mixture of claim 1 , having an average number of epoxide groups per fatty acid of being greater than 1.20.5. The isononyl ester mixture of claim 1 , having a fraction of saturated fatty acids of less than 12 area %.6. The isononyl ester mixture of claim 1 , having a fraction of saturated fatty acids of greater than 1 area %.7. A process for preparing the isononyl ester or the isononyl ester mixture of claim 1 , comprising:recovering the fatty acid or the fatty acid mixture from the tall oil or the linseed oil,epoxidizing the fatty acid or the fatty acid mixture, andesterifying the fatty acid or the fatty acid mixture with isononanol.8. A process for preparing the isononyl ester or the isononyl ester mixture of claim 1 , comprising:recovering a fatty acid ester or a fatty acid ester mixture from the tall oil or the linseed oil,epoxidizing the fatty acid ester or the fatty acid ester mixture, andtransesterifying the fatty acid ester or the fatty acid ester mixture with isononanol.9. A method for producing a polymer claim 1 , comprising: ...

Подробнее
Номер записи: 55
11-01-2018 дата публикации

FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM

Номер: US20180009773A1
Автор: FUKUMOTO Naoya, Ito Naoko, MIYASAKA Ryuta, Murofushi Katsumi, TOMITA Hiroyuki, UETAKE Shoko, YAGYU Daisuke, YAMAGUCHI Yuta
Принадлежит: SHOWA DENKO K.K.

This fluorine-containing ether compound is represented by Formula (1). 1. A fluorine-containing ether compound represented by Formula (1) ,{'br': None, 'sup': 1', '2', '3', '4', '5, 'sub': 2', '2, 'R—R—CH—R—CH—R—R\u2003\u2003(1)'}{'sup': 1', '2', '3', '4', '5, '(in Formula (1), Ris an aryl group or an aralkyl group, Ris a divalent linking group having 0 or 1 polar group, Ris a perfluoropolyether chain, Ris a divalent linking group having 2 or 3 polar groups, and Ris an aryl group or an aralkyl group.)'}2. The fluorine-containing ether compound according to claim 1 ,{'sup': 2', '4, 'wherein at least one of the polar groups in the polar groups included in Rand Rof Formula (1) is a hydroxyl group.'}3. The fluorine-containing ether compound according to claim 1 ,{'sup': 2', '4, 'wherein the polar groups included in Rand Rof Formula (1) are all hydroxyl groups.'}6. The fluorine-containing ether compound according to claim 1 ,{'sup': '1', 'wherein Rin Formula (1) is any one selected from a benzene ring group which may have a substituent, a naphthalene ring group which may have a substituent, a benzyl group which may have a substituent, or a naphthylmethyl group which may have a substituent.'}8. The fluorine-containing ether compound according to claim 1 ,{'sup': 4', '5, 'sub': 2', '2', 'z, 'wherein Rin Formula (1) has —(CH—CH—O)—O— (z in the formula represents an integer of 1 to 3) at an end on the Rside.'}9. The fluorine-containing ether compound according to claim 1 ,{'sup': '5', 'wherein Rin Formula (1) is any one selected from a benzene ring group which may have a substituent, a naphthalene ring group which may have a substituent, a benzyl group which may have a substituent, or a naphthylmethyl group which may have a substituent.'}13. The fluorine-containing ether compound according to claim 1 ,wherein a number-average molecular weight is in a range of 500 to 10,000.14. A lubricant for a magnetic recording medium claim 1 , comprising:{'claim-ref': {'@idref': 'CLM- ...

Подробнее
Номер записи: 56
14-01-2021 дата публикации

TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF

Номер: US20210009501A1
Автор: BECKER Cyrus K., Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит: CORSAIR PHARMA, INC.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension. 123-. (canceled)25. The method of claim 24 , wherein:{'sup': '3', 'sub': 1', '6, 'Rin each occurrence independently is C-Calkyl;'}{'sup': 4', '5', '4', '5, 'sub': 1', '3, 'Rand Rin each occurrence independently are hydrogen or C-Calkyl, or Rand Rand the carbon atom to which they are connected form a cyclopropyl ring;'}{'sup': 6', '3, 'Rin each occurrence independently is hydrogen or R;'}j in each occurrence independently is 0 or 1; andm in each occurrence independently is 1 or 2.28. The method of claim 24 , wherein Ris hydrogen and —ORis derivatized.29. The method of claim 24 , wherein Ris hydrogen and —ORis derivatized.30. The method of claim 24 , wherein both —OR′ and —ORare derivatized claim 24 , optionally with the same group.32. The method of claim 24 , wherein the compound is administered orally.33. The method of claim 24 , wherein the compound is administered parenterally.34. The method of claim 33 , wherein the compound is administered subcutaneously or intravenously.35. The method of claim 24 , wherein the compound is administered topically.36. The method of claim 35 , wherein the compound is administered transdermally or by oral inhalation.37. The method of claim 36 , wherein the compound is administered via a transdermal patch. The present application is a continuation of and claims priority to and the benefit of U.S. application Ser. No. 16/580,828 filed on Sep. 24, 2019, which is a continuation of Ser. No. 16/039,566, filed on Jul. 19, 2018 (now U.S. Pat. No. 10,464,878, granted on Nov. 5, 2019), which is a continuation of Ser. No. 15/617,243 filed Jun. 8, 2017 (now U.S. Pat. No. 10,053,414, granted Aug. 21, 2018), which is a continuation of Ser. No. 15/178,637 filed Jun. 10, ...

Подробнее
Номер записи: 57
10-01-2019 дата публикации

TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF

Номер: US20190010112A1
Автор: BECKER Cyrus K., Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension. 120-. (canceled)22. The pharmaceutical composition of claim 21 , which is formulated for transdermal delivery of the compound.23. The pharmaceutical composition of claim 22 , which is configured as a transdermal patch.25. The method of claim 24 , wherein the medical condition is selected from the group consisting of pulmonary hypertension claim 24 , pulmonary fibrosis claim 24 , ischemic diseases claim 24 , peripheral vascular disease claim 24 , peripheral ischemic lesions on the skin claim 24 , critical limb ischemia claim 24 , heart failure claim 24 , atherogenesis claim 24 , inflammatory diseases claim 24 , diabetic neuropathic foot ulcer claim 24 , kidney malfunction and failure claim 24 , tumors claim 24 , cancers claim 24 , and pain associated with each of the preceding conditions.26. The method of claim 25 , wherein the medical condition is pulmonary hypertension.27. The method of claim 26 , wherein the medical condition is pulmonary arterial hypertension.28. The method of claim 24 , wherein the compound is administered topically.29. The method of claim 28 , wherein the compound is administered transdermally.30. The method of claim 29 , wherein the compound is administered via a transdermal patch.31. The method of claim 28 , wherein the compound is administered pulmonarily by oral inhalation.32. The method of claim 24 , wherein the compound is administered orally.33. The method of claim 24 , wherein the compound is administered parenterally.34. The method of claim 33 , wherein the compound is administered subcutaneously or intravenously.35. The method of claim 24 , further comprising administering an additional therapeutic agent.36. The method of claim 35 , wherein the additional ...

Подробнее
Номер записи: 58
14-01-2021 дата публикации

COALESCING AGENTS FOR WATERBORNE COATINGS

Номер: US20210009844A1
Автор: ARENDT Jeffrey P., Donnelly Zuzanna, Du An, Pederson Alex R., Schneider Jeffrey A., Wu Wenjun
Принадлежит:

Compounds comprising one or more functionalized fatty acid esters, which may be derived from bio-based oils, are used as a low-VOC coalescent agent (i.e., a coalescent agent having a low content of volatile organic compounds) in waterborne coating compositions. The functional group can be epoxide, vicinal diol, hydroxy phosphotriester, hydroxy ester, hydroxyl alkyl ester, hydroxyl benzyl ester, hydroxy ether, hydroxy amino, hydroxy sulfide, hydroxy nitrile, hydroxy amine, terminal alcohol, thiiran, ketone, or cyclic carbonate. The present disclosure also relates to waterborne coating compositions comprising these functionalized fatty acid esters. 1. A coalescent agent for waterborne coatings , wherein the coalescent agent comprises one or more functionalized fatty acid C1-C22 alkyl or benzyl esters , preferably C2-C8 alkyl or benzyl esters , wherein said functionalized fatty acid esters have one or more functional groups per molecule selected from the group consisting of epoxides , excluding coalescent agents of epoxidized fatty acid methyl esters obtained from soybean oil where the alkyl is Cl (methyl epoxy esters derived from soybean oil).2. The coalescent agent of claim 1 , wherein said functionalized fatty acid esters are selected from the group consisting of monoesters claim 1 , fatty acid monoglycerides claim 1 , fatty acid esters of aliphatic mono-alcohols claim 1 , fatty acid esters of aromatic alcohols claim 1 , fatty acid esters of benzyl alcohol claim 1 , fatty acid diesters claim 1 , fatty acid diglycerides claim 1 , fatty acid esters of diols wherein both hydroxyl groups are esterified with fatty acid claim 1 , fatty acid triesters claim 1 , fatty acid triglycerides claim 1 , fatty acid esters of triols other than glycerin in which all three hydroxyl groups are esterified with fatty acid claim 1 , fatty acid esters of polyols containing more than three hydroxyl groups per molecule claim 1 , or mixtures thereof and preferably is a monoester claim 1 , ...

Подробнее
Номер записи: 59
09-01-2020 дата публикации

Novel N-3 Immunoresolvents: Structures and Actions

Номер: US20200010398A1
Автор: DALLI Jesmond, Serhan Charles N.
Принадлежит:

The invention describes novel mono-hydroxy, di-hydroxy and tri-hydroxy docosapentaenoic acid (DPA) analogues, their preparation, isolation, identification, purification and uses thereof. 19-. (canceled)11. The N-3 immunoresolvent compounds of claim 10 , wherein the compound is a pharmaceutically acceptable salt of the carboxylic acid.12. The N-3 immunoresolvent compounds of claim 10 , further comprising a carrier to provide a composition.14. The N-3 immunoresolvent compound of claim 13 , wherein the compound is a pharmaceutically acceptable salt of the carboxylic acid.15. The N-3 immunoresolvent compound of claim 13 , further comprising a carrier to provide a composition.16. A method to treat or prevent one or more of inflammation claim 10 , arterial inflammation claim 10 , arthritis claim 10 , psoriasis claim 10 , urticara claim 10 , vasculitis claim 10 , asthma claim 10 , ocular inflammation claim 10 , pulmonary inflammation claim 10 , pulmonary fibrosis claim 10 , seborrheic dermatitis claim 10 , pustular dermatosis claim 10 , cardiovascular diseases claim 10 ,recruitment of neutrophils claim 10 , leukocytes and/or cytokines claim 10 , Addiction claim 10 , AIDS claim 10 , Alcohol-related disorders claim 10 , Allergy claim 10 , Alzheimer's disease claim 10 , Anesthesiology claim 10 , Anti-infectives claim 10 , Anti-inflammatory agents claim 10 , Arthritis claim 10 , Asthma claim 10 , Atherosclerosis claim 10 , Bone diseases claim 10 , Breast cancer claim 10 , Cancer claim 10 , Cardiovascular diseases claim 10 , Child health claim 10 , Colon cancer claim 10 , Congenital defects claim 10 , Decision analysis claim 10 , Degenerative neurologic disorders claim 10 , Dementia claim 10 , Dermatology claim 10 , Diabetes mellitus claim 10 , Diagnostics claim 10 , Drug delivery claim 10 , Drug discovery/screen claim 10 , Endocrine disorders claim 10 , ENT claim 10 , Epidemiology claim 10 , Eye diseases claim 10 , Fetal and maternal medicine claim 10 , Gastrointestinal ...

Подробнее
Номер записи: 60
09-01-2020 дата публикации

PROCESSES FOR PREPARING PARTIALLY FLUORINATED EPOXIDES AND PERFLUORINATED EPOXIDES AND COMPOSITIONS RELATED THERETO

Номер: US20200010439A1
Автор: Brandt Drew Richard, PETROV VIACHESLAV A
Принадлежит: THE CHEMOURS COMPANY FC, LLC

This application relates to the preparation of partially fluorinated epoxides and perfluorinated epoxides which may be useful in various applications including refrigerants, heat transfer media, high-temperature heat pumps, organic Rankine cycles, fire extinguishing/fire suppression, propellants, foam blowing, solvents, gaseous dielectrics, and/or cleaning fluids. Compositions comprising the fluorinated epoxide compounds are also provided. 2. (canceled)3. (canceled)4. The process of claim 1 , wherein Rand Rare each independently H or F; and Rand Rare each independently selected from partially fluorinated or perfluorinated Calkyl.5. The process of claim 1 , wherein the hypohalite salt is selected from NaOCl claim 1 , KOCl claim 1 , NaOBr claim 1 , and Ca(OCl).6. (canceled)7. The process of claim 1 , wherein the cationic phase transfer catalyst is a quaternary ammonium salt or a quaternary phosphonium salt.8. (canceled)9. The process of claim 1 , the cationic phase transfer catalyst has formula (R)(R)(R)(R)NX or (R)(R)(R)(R)PX claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare each independently selected from Calkyl claim 1 , Ccycloalkyl claim 1 , 4-14 membered heterocycloalkyl claim 1 , Caryl claim 1 , 5-14 membered heteroaryl claim 1 , Ccycloalkyl-Calkylene claim 1 , 4-14 membered heterocycloalkyl-Calkylene claim 1 , Cmembered aryl-Calkylene claim 1 , and 5-14 membered heteroaryl-Calkylene claim 1 , each of which is optionally substituted by 1 claim 1 , 2 claim 1 , 3 claim 1 , or 4 groups independently selected from OH claim 1 , Calkoxy claim 1 , Calkyl claim 1 , Calkenyl claim 1 , Cfluoroalkyl claim 1 , di-(Calkyl)amino claim 1 , Ccycloalkyl claim 1 , 4-14 membered heterocycloalkyl claim 1 , Cmembered aryl claim 1 , and 5-14 membered heteroaryl; and X is an anion.10. The process of claim 1 , wherein the cationic phase transfer catalyst has formula (R)(R)(R)(R)NX claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , and Rare eah independently selected ...

Подробнее
Номер записи: 61
09-01-2020 дата публикации

HIGH HEAT MONOMERS AND METHODS OF USE THEREOF

Номер: US20200010608A1
Автор: Fisher Scott Michael, PAL JAYKISOR, Peters Edward Norman
Принадлежит:

High purity epoxide compounds methods for preparing the high purity epoxide compounds, and compositions derived from the epoxide compounds are provided. Also provided are materials and articles derived from the epoxide compounds. 3. The compound of claim 1 , wherein the compound has a purity of 97% or greater claim 1 , as determined by high performance liquid chromatography (HPLC).4. The compound of claim 1 , wherein the compound is substantially free of oligomer impurities.6. The compound of claim 1 , having a softening point of less than 50° C. claim 1 , as measured according to ASTM E28-1999.8. The process of claim 7 , wherein the base is sodium hydroxide or potassium hydroxide.9. The process of claim 7 , wherein the compound of formula (1) has a purity of 99% or greater claim 7 , as determined by high performance liquid chromatography.11. The curable composition of claim 10 , wherein the auxiliary epoxy resin is selected from aliphatic epoxy resins claim 10 , cycloaliphatic epoxy resins claim 10 , bisphenol A epoxy resins claim 10 , bisphenol-F epoxy resins claim 10 , phenol novolac epoxy resins claim 10 , cresol-novolac epoxy resins claim 10 , biphenyl epoxy resins claim 10 , polyfunctional epoxy resins claim 10 , naphthalene epoxy resins claim 10 , divinylbenzene dioxide claim 10 , 2-glycidylphenylglycidyl ether claim 10 , dicyclopentadiene-type epoxy resins claim 10 , multi aromatic resin type epoxy resins claim 10 , and mixtures thereof.12. The curable composition of claim 10 , wherein the auxiliary epoxy resin is a diglycidyl ether of 2 claim 10 ,2-bis(4-hydroxyphenyl)propane.13. The curable composition of claim 10 , wherein the curing promoter is an amine compound selected from isophoronediamine claim 10 , triethylenetetraamine claim 10 , diethylenetriamine claim 10 , aminoethylpiperazine claim 10 , 1 claim 10 ,2- and 1 claim 10 ,3-diaminopropane claim 10 , 2 claim 10 ,2-dimethylpropylenediamine claim 10 , 1 claim 10 ,4-diaminobutane claim 10 , 1 claim 10 ...

Подробнее
Номер записи: 62
14-01-2016 дата публикации

ELECTROPHOTOGRAPHIC PHOTOSENSITIVE MEMBER, PROCESS CARTRIDGE, ELECTROPHOTOGRAPHIC APPARATUS, AND CONDENSED POLYCYCLIC AROMATIC COMPOUND

Номер: US20160011529A1
Автор: Kosaka Nobuo, NAKATA Koichi, Takagi Shinji
Принадлежит:

Provided are an electrophotographic photosensitive member which satisfies wear resistance and electrical characteristics, and in which image deletion is satisfactorily suppressed, and a process cartridge and an electrophotographic apparatus each including the electrophotographic photosensitive member. The electrophotographic photosensitive member comprises a surface layer which includes a polymerized product of a hole transporting substance having a reactive functional group, in which a structure other than the reactive functional group of the hole transporting substance is one of: a structure consisting of a carbon atom and a hydrogen atom; and a structure consisting of a carbon atom, a hydrogen atom and an oxygen atom, and the structure other than the reactive functional group of the hole transporting substance comprises a specific conjugate structure. 1. An electrophotographic photosensitive member comprising:a support; anda photosensitive layer formed on the support,wherein a surface layer of the electrophotographic photosensitive member comprises a polymerized product of a hole transporting substance having a reactive functional group, wherein,a structure other than the reactive functional group of the hole transporting substance is one of:a structure consisting of a carbon atom and a hydrogen atom; anda structure consisting of a carbon atom, a hydrogen atom and an oxygen atom,{'sup': '2', 'the structure other than the reactive functional group of the hole transporting substance comprises a structure which comprises a conjugate structure comprising 24 or more spcarbon atoms, and wherein,'}{'sup': '2', 'the conjugate structure comprises a condensed polycyclic structure comprising 12 or more spcarbon atoms.'}2. The electrophotographic photosensitive member according to claim 1 , wherein the hole transporting substance comprises two or more units of the condensed polycyclic structures.3. The electrophotographic photosensitive member according to claim 1 , wherein ...

Подробнее
Номер записи: 63
21-01-2016 дата публикации

Complexes useful as active components in supported epoxidation catalysts

Номер: US20160016157A1
Автор: Barbara Kimmich, Daniel F. White, Debra L. JACKSON, Ilya E. Nifant'ev, Pavel V. Ivchenko, Sandor Nagy
Принадлежит: Lyondell Chemical Technology LP

Method of preparing epoxidation catalysts are disclosed, including methods comprising reacting an inorganic siliceous solid with a metal complex of the formulas: wherein the variables are defined herein.

Подробнее
Номер записи: 64
17-01-2019 дата публикации

Selective androgen receptor degrader (sard) ligands and methods of use thereof

Номер: US20190015387A1
Автор: Dong-Jin Hwang, Duane D. Miller, Ramesh Narayanan, Thamarai Ponnusamy, Yali He
Принадлежит: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Подробнее
Номер записи: 65
18-01-2018 дата публикации

TREPROSTINIL DERIVATIVES AND COMPOSITIONS AND USES THEREOF

Номер: US20180016222A1
Автор: BECKER Cyrus K., Venkatraman Meenakshi S., Zhang Xiaoming
Принадлежит:

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension. 120-. (canceled)22. The pharmaceutical composition of claim 21 , wherein n is an integer from 1 to 6.24. The pharmaceutical composition of claim 23 , wherein both Rand Rare hydrogen claim 23 , and p is an integer from 1 to 9 or from 1 to 5 (or each occurrence of Rand Ris hydrogen claim 23 , and q is an integer from 0 to 8 or from 0 to 4).27. The pharmaceutical composition of claim 21 , wherein —O—Z—COH is —O-cycloalkyl-COH claim 21 , —O—CH-cycloalkyl-COH claim 21 , —O-cycloalkyl-CH—COH claim 21 , or —O—CH-cycloalkyl-CH—COH claim 21 , and for each of the preceding moieties -cycloalkyl- is:1,2-cyclopropyl (cis or trans); or1,3-cyclobutyl (cis or trans) or 1,2-cyclobutyl (cis or trans); or1,3-cyclopentyl (cis or trans) or 1,2-cyclopentyl (cis or trans); or1,4-cyclohexyl (cis or trans), 1,3-cyclohexyl (cis or trans), or 1,2-cyclohexyl (cis or trans).29. The pharmaceutical composition of claim 21 , which is formulated for transdermal delivery of the compound of Formula (II).30. The pharmaceutical composition of claim 29 , which is configured as a transdermal patch.32. The compound of claim 31 , wherein n is 3 claim 31 , 4 claim 31 , 5 or 6.34. The compound of claim 33 , wherein p is 2 claim 33 , 3 claim 33 , 4 or 5.35. A pharmaceutical composition comprising a compound of or a pharmaceutically acceptable salt claim 31 , solvate claim 31 , hydrate claim 31 , clathrate claim 31 , polymorph or stereoisomer thereof claim 31 , and one or more pharmaceutically acceptable excipients or carriers.36. The pharmaceutical composition of claim 35 , which is formulated for transdermal delivery of the compound.37. A method of treating a medical condition responsive to treatment with treprostinil claim 31 , ...

Подробнее
Номер записи: 66
18-01-2018 дата публикации

EPOXIDATION PROCESS

Номер: US20180016248A1
Автор: Padia Ashok S.
Принадлежит: Scientific Design Company, Inc.

A method for producing ethylene oxide comprising: a) providing one or more feed components, wherein the one or more feed components contains at least ethylene obtained by dehydrating ethanol; b) contacting the one or more feed components with an ethylene oxide catalyst bed disposed in a reactor tube, the ethylene oxide catalyst bed comprising: (1) an upstream ethylene oxide catalyst having a first cesium concentration and (2) a downstream ethylene oxide catalyst having a second cesium concentration, wherein the first cesium concentration is higher than the second cesium concentration. 1. A method for producing ethylene oxide comprising:a) providing one or more feed components, wherein the one or more feed components contain at least ethylene;b) contacting the one or more feed components with an ethylene oxide catalyst bed disposed in a reactor tube, the ethylene oxide catalyst bed comprising: (1) an upstream ethylene oxide catalyst having a first cesium concentration and (2) a downstream ethylene oxide catalyst having a second cesium concentration, wherein the first cesium concentration is higher than the second cesium concentration.2. The method of claim 1 , wherein the ethylene is obtained by dehydrating ethanol.3. The method of claim 1 , wherein the ethylene is obtained from petroleum sources.4. The method of claim 1 , wherein the ethylene oxide catalyst bed comprises from about 10 wt % to about 90 wt % of the upstream ethylene oxide catalyst and about 10 wt % to about 90 wt % of the downstream epoxidation catalyst.5. The method of claim 1 , wherein the first cesium concentration is from about 200 ppm to about 1000 ppm and the second cesium concentration is from about 100 ppm to about 700 ppm.6. The method according to claim 1 , wherein the one or more feed components further comprises oxygen and a ballast gas.7. A system for producing ethylene oxide comprising:(a) a source of ethylene;(b) an ethylene oxide reactor containing a plurality of reactor tubes; and(c) ...

Подробнее
Номер записи: 67
18-01-2018 дата публикации

Methods of Treating an Overweight or Obese Subject

Номер: US20180016249A1
Автор: Vath James E.
Принадлежит:

The disclosure herein generally relates to methods of treating an overweight or obese condition, and overweight- or obesity-related conditions. In one embodiment, the disclosure provides a method of treating an overweight or obese condition involving administering to the subject in need thereof, an amount of a pharmaceutical composition including a MetAP-2 inhibitory compound, or a salt, ester, or prodrug thereof, effective to result in weight loss in the subject. 3. The method of claim 1 , wherein the subject has a Body Mass Index measurement selected from the group consisting of: at least about 25 kg/m claim 1 , at least about 30 kg/m claim 1 , and at least about 40 kg/m.412.-. (canceled)14. (canceled) This application is a continuation of U.S. Ser. No. 14/802,473, filed Jul. 17, 2015, which is a continuation of U.S. Ser. No. 14/616,002, filed Feb. 6, 2015, which is a continuation of U.S. Ser. No. 13/133,062, filed Sep. 22, 2011, (now abandoned) which is a national phase filing under 35 U.S.C. §371 of PCT/US2009/066809, filed Dec. 4, 2009, which claims priority to U.S. provisional applications U.S. Ser. No. 61/119,875 filed Dec. 4, 2008, U.S. Ser. No. 61/119,881 filed Dec. 4, 2008, U.S. Ser. No. 61/119,884 filed Dec. 4, 2008, U.S. Ser. No. 61/119,886 filed Dec. 4, 2008, U.S. Ser. No. 61/275,688 filed Aug. 3, 2009, and U.S. Ser. No. 61/260,194 filed Nov. 11, 2009, each application of which is hereby incorporated by reference in its entirety.Obesity is a complex medical disorder of appetite regulation and metabolism resulting in excessive accumulation of adipose tissue mass. Typically defined as a body mass index (BMI) of 30 kg/mor more, obesity is a world-wide public health concern that is associated with cardiovascular disease, diabetes, certain cancers, respiratory complications, osteoarthritis, gallbladder disease, decreased life expectancy, and work disability. The primary goals of obesity therapy are to reduce excess body weight, improve or prevent obesity- ...

Подробнее
Номер записи: 68
15-01-2015 дата публикации

Process for preparing cis-5-[1-(4-chlorophenyl)-methylene]-1-hydroxymethyl-2,2-dimethylcyclopentanol

Номер: US20150018560A1
Автор: Kemper Paul, ZIERKE Thomas
Принадлежит: BASf ARGO B.V. ARNHEM (NL). ZURICH-BRANCH

The present invention relates to a process for preparing a diol of the formulae (Ia) or (Ib), or a mixture thereof, 117-. (canceled)19. The process of claim 18 , wherein the reaction with sodium borohydride and aluminum(III) chloride is carried out in an organic solvent selected from ethers.20. The process of claim 19 , wherein the organic solvent is selected from tetrahydrofuran claim 19 , dioxane claim 19 , glyme claim 19 , diglyme claim 19 , triglyme and mixtures thereof.21. The process of claim 18 , wherein the borohydride is used in an amount of 0.8 to 2.0 mol and the aluminum(III) chloride is used in an amount of 0.4 to 1.1 mol claim 18 , based in each case on 1 mol of the epoxy alcohol of formula (Va) or (Vb) claim 18 , or a mixture thereof.22. The process of wherein the borohydride is used in an amount of 1.2 to 1.5 mol claim 21 , based on 1 mol of the epoxy alcohol of formula (Va) or (Vb) claim 21 , or a mixture thereof.24. The process of claim 23 , wherein the reduction in step (b) is performed using an alkali metal borohydride as reducing agent.25. The process of claim 23 , wherein the reduction in step (b) is a Meerwein-Ponndorf-Verley reduction.26. The process of claim 23 , wherein in step (c) the allylic alcohol of the formula (IV) is enantioselectively converted into the epoxy alcohol of formula (Va) or into the epoxy alcohol of formula (Vb).28. The process according to claim 27 , wherein the reducing agent in step (c′) is an alkali metal borohydride.30. The process of claim 29 , wherein the isomerization is carried out in the presence of an aqueous solution of hydrochloric acid having a concentration of 20 to 37% by weight.31. The process of claim 29 , wherein the solvent or solvent mixture in which the isomerization of step (a) is carried out is not claim 29 , or is only partly claim 29 , removed before the reduction of step (b) is initiated claim 29 , provided the process comprises the step (b).33. The process according to claim 32 , wherein (−)- ...

Подробнее
Номер записи: 69
21-01-2021 дата публикации

PROCESS FOR THE PREPARATION OF GLYCIDOL

Номер: US20210017142A1
Автор: Atkins Martin, Coleman Fergal, Hardiman Sean
Принадлежит:

This invention relates to a process for the preparation of glycidol from the thermal decarboxylation of glycerol carbonate. In one aspect, the present invention provides a process for the preparation of glycidol by thermal decarboxylation of glycerol carbonate, said process comprising the steps of: 1. A process for the preparation of glycidol by thermal decarboxylation of glycerol carbonate , said process comprising the steps of:a) contacting liquid glycerol carbonate with a decarboxylation promotor, having a boiling point of at least 160° C. at atmospheric pressure and consisting essentially of an aliphatic mono-ol, an aliphatic polyol, or mixtures thereof, to form a liquid phase mixture;b) applying heat to the liquid phase mixture formed in step a) to induce thermal decarboxylation of the glycerol carbonate; andc) separating glycidol formed in step b) from the liquid phase mixture by evaporation of glycidol; andwherein the process does not comprise the use of a decarboxylation catalyst.2. A process according to claim 1 , wherein the mono-ol and/or polyol is acyclic.3. A process according to or claim 1 , wherein the mono-ol and/or polyol comprise one or more ether groups.4. A process according to any one of the preceding claims claim 1 , wherein the mono-ol and/or polyol has a plurality of ether groups and a primary hydroxyl group.5. A process according to any one of the preceding claims claim 1 , wherein the polyol is selected from polyethylene glycol claim 1 , polypropylene glycol claim 1 , and oligomers of ethylene glycol claim 1 , propylene glycol and glycerol.6. A process according to claim 5 , wherein the polyol is selected from oligomers of ethylene glycol claim 5 , propylene glycol and glycerol claim 5 , each having from 2 to 8 repeat monomer units claim 5 , preferably from 2 to 5 repeat monomer units.7. A process according to claim 6 , wherein the polyol is an oligomer selected from tripropylene glycol claim 6 , tetrapropylene glycol claim 6 , triethylene ...

Подробнее
Номер записи: 70
26-01-2017 дата публикации

Method for the production of high-purity glycerol dimethacrylate

Номер: US20170022142A1
Автор: Joachim Knebel, Maik Caspari, Volker Herzog
Принадлежит: Evonik Roehm GmbH

The present invention claims a process for preparing high-purity glycerol dimethacrylate comprising <500 ppm of glycidyl methacrylate, characterized in that an aftertreatment with acidic adsorbent is effected.

Подробнее
Номер записи: 71
25-01-2018 дата публикации

POLYMERIZABLE COMPOUND AND OPTICAL ISOMER

Номер: US20180022716A1
Автор: Horiguchi Masahiro, Kadomoto Yutaka
Принадлежит: DIC CORPORATION

The present invention provides a polymerizable compound having high storage stability without causing crystal precipitation when added to a polymerizable composition. The present invention also provides a polymerizable composition containing the compound. When the filmy polymer produced through polymerization of the polymerizable composition is irradiated with UV light, it hardly discolors or peels from substrate. Further, the present invention provides a polymer produced through polymerization of the polymerizable composition and an optically anisotropic body using the polymer. 4. The compound according to claim 2 , wherein in the formula (I-R) claim 2 , Sp each independently represents an alkylene group having 1 to 20 carbon atoms in which one —CH— or two or more of (—CH—)'s which are not adjacent to each other may be each independently substituted with —O— claim 2 , —COO— claim 2 , —OCO— claim 2 , —OCO—O— claim 2 , —CO—NH— claim 2 , —NH—CO— claim 2 , —CH═CH— or —C≡C—.5. A composition containing the compound of .6. A liquid crystal composition containing the compound of .7. A polymer obtained through polymerization of the composition of .8. An optically anisotropic body using the polymer of .9. Resins claim 1 , resin additives claim 1 , oils claim 1 , filters claim 1 , adhesives claim 1 , pressure-sensitive adhesives claim 1 , oils and fats claim 1 , inks claim 1 , medicines claim 1 , cosmetics claim 1 , detergents claim 1 , building materials claim 1 , wrapping or packaging materials claim 1 , liquid crystal materials claim 1 , organic EL materials claim 1 , organic semiconductor materials claim 1 , electronic materials claim 1 , display devices claim 1 , electronic devices claim 1 , communication instruments claim 1 , automobile parts claim 1 , airplane parts claim 1 , machine parts claim 1 , agricultural chemicals and foods using the compound of . The present invention relates to a compound having a polymerizable group, a polymerizable composition containing ...

Подробнее
Номер записи: 72
25-01-2018 дата публикации

COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE

Номер: US20180023001A1
Автор: KONDOU Fumitaka, OGITA Kazuhiro, Tanaka Hiroyuki, YANO Masakazu
Принадлежит:

Provided is a polar compound that has high chemical stability and high capability of aligning liquid crystal molecules, and has a large voltage holding ratio when used in a liquid crystal display device. 2. The compound according to claim 1 , wherein claim 1 , in the formula (1) claim 1 , Ris a group represented by formula (1a) or formula (1b).3. The compound according to claim 1 , wherein claim 1 , in the formula (1) claim 1 , d is 1 or 2 claim 1 , and a sum of c claim 1 , d and e is 1 claim 1 , 2 claim 1 , 3 or 4.10. A liquid crystal composition claim 1 , containing at least one compound according to .18. The liquid crystal composition according to claim 15 , further containing at least one of a polymerizable compound other than formula (1) and formula (16) claim 15 , a polymerization initiator claim 15 , a polymerization inhibitor claim 15 , an optically active compound claim 15 , an antioxidant claim 15 , an ultraviolet light absorber claim 15 , a light stabilizer claim 15 , a heat stabilizer and an antifoaming agent.19. A liquid crystal display device claim 10 , including at least one liquid crystal composition according to . The invention relates to a compound having a polymerizable group, a liquid crystal composition and a liquid crystal display device. More specifically, the invention relates to a compound simultaneously having a polymerizable group such as methacryloiloxy and a polar group such as a —OH group, a liquid crystal composition that contains the compound and has positive or negative dielectric anisotropy, and a liquid crystal display device including the composition.In a liquid crystal display device, a classification based on an operating mode for liquid crystal molecules includes a phase change (PC) mode, a twisted nematic (TN) mode, a super twisted nematic (STN) mode, an electrically controlled birefringence (ECB) mode, an optically compensated bend (OCB) mode, an in-plane switching (IPS) mode, a vertical alignment (VA) mode, a fringe field ...

Подробнее
Номер записи: 73
10-02-2022 дата публикации

PHENOL DERIVATIVE, AND PREPARATION PROCESS AND USE THEREOF

Номер: US20220041535A1
Автор: Chen Xiaowei, LIANG Yuxiang, Wei Kecheng
Принадлежит:

A phenol derivative of the present invention has a structure as represented by the formula (I): 9. The preparation process according to claim 8 , which is characterized in that the compound represented by the general formula (I′) can be subjected to at least one reaction of an epoxidation reaction claim 8 , a sulfurization reaction and a coupling reaction in the first step claim 8 , followed by one or more reactions of an optional esterification reaction claim 8 , an optional alkylation reaction and an optional hydrogenation reaction in the second step; or the compound represented by the general formula (I′) can be subjected to one or more reactions of an optional esterification reaction claim 8 , an optional alkylation reaction and an optional hydrogenation reaction in the second step claim 8 , followed by at least one reaction of an epoxidation reaction claim 8 , a sulfurization reaction and a coupling reaction in the first step.10. The preparation process according to claim 8 , which is characterized in that the process further comprises a third step of subjecting to at least one reaction selected from an epoxidation reaction claim 8 , a sulfurization reaction and a coupling reaction and different from the reactions in the first step.11. The preparation process according to claim 8 , which is characterized in that the epoxidation reaction is to react —C═C— in the compound represented by the formula (I′) with an epoxidizing agent claim 8 , or to react a product obtained from subjecting the compound represented by the formula (I′) to one or more reactions of an optional esterification reaction claim 8 , an optional alkylation reaction and an optional hydrogenation reaction in the second step with an epoxidizing agent claim 8 , preferably claim 8 , the epoxidizing agent is preferably a peroxide claim 8 , for example can be selected from one or more of hydrogen peroxide claim 8 , peroxyformic acid claim 8 , peroxyacetic acid claim 8 , peroxysulfonic acid claim 8 , m- ...

Подробнее
Номер записи: 74
22-01-2015 дата публикации

DOCOSAHEXAENOYL ETHANOLAMIDES

Номер: US20150025257A1
Автор: Serhan Charles N., YANG RONG
Принадлежит: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

The invention describes novel mono or dihydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. 114.-. (canceled)16. The compound of claim 15 , wherein Pand Pare both hydrogen atoms.17. The compound of claim 15 , wherein Z is —C(O)NRR—OH.18. The compound of claim 17 , wherein one Ris H and the second Ris ethyl.20. The purified compound of claim 19 , wherein Pand Pare both hydrogen atoms.21. The purified compound of claim 19 , wherein Z is —C(O)ORand Rof Z is a hydrogen atom.22. The purified compound of claim 19 , wherein Z is —C(O)NRR—OH.23. The purified compound of claim 22 , wherein one Ris H and the second Ris ethyl.24. The compound of claim 15 , wherein the hydrogen atom on one or more hydroxyl containing carbon atoms is substituted with an alkyl group.25. The purified compound of claim 19 , wherein the hydrogen atom on one or more hydroxyl containing carbon atoms is substituted with an alkyl group.26. The compound of claim 15 , wherein the alkyl group is a methyl group.27. The purified compound of claim 19 , wherein the alkyl group is a methyl group.28. The compound of claim 15 , further comprising a pharmaceutically acceptable carrier.29. The compound of claim 19 , further comprising a pharmaceutically acceptable carrier.30. A method to treat or prevent inflammation claim 15 , cancer claim 15 , neurodegeneration claim 15 , memory loss claim 15 , neuroinflammation or traumatic brain injury comprising the step of administering to an individual in need thereof claim 15 , an effective amount of the compound of .31. A method to treat or prevent inflammation claim 19 , cancer claim 19 , neurodegeneration claim 19 , memory loss claim 19 , neuroinflammation or traumatic brain injury comprising the step of administering to an individual in need thereof claim 19 , an effective amount of the compound of .32. A method to treat neural development claim 15 , fetal development claim 15 , homeostasis claim 15 ...

Подробнее
Номер записи: 75
10-02-2022 дата публикации

QUATERNARY AMMONIUM SALTS AS INHIBITORS OF TRIMETHYLAMINE PRODUCTION

Номер: US20220041641A1
Автор: AJAYI Kehinde, BILLINGS Gabriel, BOGART Elijah, Briggs Timothy, DOUD Devin Forest Reed, GUNASEKERA Dinara Shashanka, LAFRANCE Danny, LIU Jenny, MARTINEZ-DEL CAMPO Ana, NUDEL Kathleen, PECK Spencer Cory, PROUDFOOT John, ROSS Cheri, Taylor Steven, TEFFERA Yohannes, YASUDA Koji
Принадлежит:

Provided are compounds that can inhibit pathogenic, bacterial metabolite production and conjugates of the same. Also provided are pharmaceutical compositions comprising the same and methods of using the same. 5. The compound of claim 4 , wherein Ris Calkyl substituted with —O-(acylated sugar) and is optionally further substituted with oxo.6. The compound of or claim 4 , wherein Ris methyl.7. The compound of any one of claim 4 , claim 4 , and claim 4 , wherein Ris Calkyl.8. The compound of any one of - claim 4 , wherein Ris propargyl.9. The compound of claim 4 , wherein{'sup': '1', 'sub': '2-6', 'Ris Calkyl substituted with —O-(acylated sugar) and is optionally further substituted with oxo;'}{'sup': '2', 'Ris methyl;'}{'sup': '3', 'sub': '1-6', 'Ris Calkyl; and'}{'sup': '4', 'Ris propargyl.'}10. The compound of claim 4 , wherein{'sup': '1', 'sub': '2-6', 'Ris Calkyl substituted with isosorbide and is optionally further substituted with oxo and/or methene;'}{'sup': '2', 'Ris methyl;'}{'sup': '3', 'sub': '1-6', 'Ris Calkyl; and'}{'sup': '4', 'Ris propargyl.'}13. The compound of claim 4 , wherein{'sup': '1', 'sub': 3-4', '1-2, 'Ris Ccycloalkyl Calkyl;'}{'sup': '2', 'sub': '2-6', 'Ris Calkyl optionally substituted with one or two hydroxyl, oxo, and —O-(acylated sugar);'}{'sup': 1', '2', 's', 's, 'sub': 2', 'n, 'or Rand R, together with the nitrogen atom to which both are attached, combine to form a 4- or 5-membered heterocyclic ring optionally substituted with ethynyl or —(CH)—ORor an acylated sugar, wherein n is 0 or 1, Ris hydrogen or an acylated sugar;'}{'sup': '3', 'sub': '1-6', 'Ris Calkyl optionally substituted with a halogen or hydroxyl; and'}{'sup': '4', 'sub': '1-6', 'Ris Calkyl or propargyl.'}14. The compound of claim 13 , wherein Ris Ccycloalkyl Calkyl.15. The compound of or claim 13 , wherein Ris Calkyl optionally substituted with one or two hydroxyl groups.16. The compound of claim 13 , wherein Rand R claim 13 , together with the nitrogen atom to which both ...

Подробнее
Номер записи: 76
24-01-2019 дата публикации

METHODS FOR DIRECT EPOXIDATION OF PROPYLENE WITH OXYGEN

Номер: US20190023672A1
Автор: Nijhuis Tjeerd Alexander, Odeh Ihab N.
Принадлежит:

Methods to produce propylene oxide are described. One method can include providing a propene feedstream, an oxygen feed stream and, optionally, a hydrogen feed stream to a reaction zone, and maintaining, in a reaction zone during the reaction, at least 50 vol. % propene and 1 to 15 vol. % Oby gradually introducing a feed stream that includes the Oover the length of the catalytic bed or the length of the reaction zone and/or a feed stream that includes the Hover the length of the catalytic bed or the length of the reaction zone. 1. A method for direct epoxidation of propene , the method comprising reacting , in a reaction zone of a reactor , propene , oxygen gas (O) , and hydrogen gas (H) in the presence of a catalytic bed that includes a propene epoxidation catalyst to produce a product stream comprising propylene oxide , wherein:{'sub': 2', '2', '2', '2, 'at least 50 vol. % propene, 1 to 15 vol. % O, and 1 to 15 vol. % His maintained in the reaction zone during the reaction by (i) introducing the propene through a first reactant feed stream and (ii) gradually introducing the Oor the H, or both, over the length of the catalytic bed or the length of the reaction zone through a separate reactant feed stream(s), and'}a temperature of 150° C. to 300° C. and a pressure of 3 bar to 20 bar is maintained in the reaction zone during the reaction.2. The method of claim 1 , wherein 82 vol. % to 95 vol. % of propene claim 1 , 3 vol. % to 8 vol. % O claim 1 , and 2 vol. % to 10 vol. % His maintained in the reaction zone during the reaction.3. The method of claim 2 , wherein 88 vol. % to 92 vol. % of propene claim 2 , 4 vol. % to 6 vol. % O claim 2 , and 4 vol. % to 6 vol. % His maintained in the reaction zone during the reaction.4. The method of claim 1 , wherein the vol. % of propene and Oor H claim 1 , or both claim 1 , in the reaction zone has an explosive regime claim 1 , and wherein the gradual introduction of Oor H claim 1 , or both claim 1 , in the reaction zone is such ...

Подробнее
Номер записи: 77
24-01-2019 дата публикации

PROCESS FOR THE EPOXIDATION OF AN OLEFIN

Номер: US20190023673A1
Автор: DAUTH Nico, PASCALY Matthias, Schmidt Franz
Принадлежит:

In a process for the epoxidation of an olefin with hydrogen peroxide in the presence of a solvent, where a mixture comprising olefin, an aqueous hydrogen peroxide solution and a solvent is continuously passed through a fixed bed of an epoxidation catalyst comprising a titanium zeolite, addition of a chelating agent to the aqueous hydrogen peroxide solution before mixing it with solvent reduces or prevents formation of deposits on the catalyst and blocking of orifices of a liquid distributor. 114-. (canceled)15. A process for the epoxidation of an olefin with hydrogen peroxide in the presence of a solvent , wherein the solvent is selected from the group consisting of methanol , ethanol , tert-butanol , ethylene glycol , 1 ,2-propanediol , 1 ,3-propanediol , tetrahydrofuran , dioxane , ethylene glycol monomethyl ether , ethylene glycol monoethyl ether , ethylene glycol monobutyl ether , propylene glycol monomethyl ethers , acetone , 2-butanone , acetonitrile and proprionitrile , hydrogen peroxide is used as an aqueous hydrogen peroxide solution , a chelating agent is added to the aqueous hydrogen peroxide solution before it is mixed with solvent , and a mixture comprising olefin , solvent , and hydrogen peroxide with added chelating agent is continuously passed through a fixed bed of an epoxidation catalyst comprising a titanium zeolite.16. The process of claim 15 , wherein the aqueous hydrogen peroxide solution comprises phosphoric acid or an alkali metal or ammonium salt of phosphoric acid.17. The process of claim 15 , wherein the aqueous hydrogen peroxide solution is mixed with at least 50% of the solvent used for reacting the olefin with hydrogen peroxide.18. The process of claim 15 , wherein the chelating agent is a polyphosphonic acid or an alkali metal or ammonium salt thereof.19. The process of claim 15 , wherein the chelating agent is added in an amount of from 10to 10mol chelating agent per mol of hydrogen peroxide.20. The process of claim 15 , wherein the ...

Подробнее
Номер записи: 78
24-01-2019 дата публикации

FUMAGILLOL SPIROCYCLIC COMPOUNDS AND FUSED BICYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME

Номер: US20190023716A1
Автор: Cai Zhenwei, Vath James E., Wu Zhixing, Zahler Robert
Принадлежит:

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2. 2. The method of claim 1 , wherein Rand R claim 1 , together with the carbon or carbons to which they are attached claim 1 , form a 4-membered saturated heterocyclic ring B having one NR.3. The method of claim 1 , wherein Rand R claim 1 , together with the carbon or carbons to which they are attached claim 1 , form a 4 membered saturated heterocyclic ring B having one S(O).6. The method of claim 5 , wherein Ris selected from the group consisting of hydrogen and Calkyl optionally substituted by one or more fluorine atoms.11. A method of treating Prader-Willi syndrome in a patient in need thereof claim 5 , comprising administering to the patient an effective amount of a compound selected from the group consisting of:(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 2-oxa-6-azaspiro[3.3]heptane-6-carboxylate;(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 7-oxa-2-azaspiro[3.5]nonane-2-carboxylate;(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 6-oxa-2-azaspiro[3.4]octane-2-carboxylate;(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 7-methyl-2,7-diazaspiro[3.5]nonane-2-carboxylate;(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 7-(2,2-difluoroethyl)-2,7-diazaspiro[3.5]nonane-2-carboxylate;(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl 6-methyl-2,6-diazaspiro[3.3]heptane-2-carboxylate;(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3- ...

Подробнее
Номер записи: 79
23-01-2020 дата публикации

Heat-resistant polylactic acid continuously-extruded foamed material and preparation method thereof

Номер: US20200024243A1
Автор: CHEN Huxiao, Li Peng, Lu Dan, Wang Xiong
Принадлежит: NINGBO HOMELINK ECO-ITECH CO., LTD.

An ethylene bis-12-hydroxystearamide grafted glycidyl citrate (EBH-g-ECA) and a preparation method thereof are provided; the EBH-g-ECA can be used as a multifunctional auxiliary agent in a polymer material, and particularly has a chain extension and a crystal nucleation effect in a polyester polymer material. A heat-resistant polylactic acid continuously-extruded foamed material containing EBH-g-ECA is further provided. The continuous foaming technology can be realized by using the heat-resistant polylactic acid foamed material, and the prepared foamed product has a high heat resistance, a uniform appearance, a low density, and complete biodegradation. A polylactic acid foamed material preparation method for a heat-resistant is provided, which is easy to be industrialized and has a great significance for realizing the large-scale replacement of petroleum-based plastic disposable foamed products such as PP and PS. 6. The method according to claim 5 , whereinthe first catalyst in step S1a is at least one selected from the group consisting of potassium carbonate and sodium carbonate;in the step S1a, the first solvent is at least one selected from the group consisting of chloroform, toluene and tetrahydrofuran;in step S1a, conditions of reacting by heating are 20° C.-60° C., and 30-60 h;in step S1a, a molar ratio of the citric acid, the oxalyl chloride, the ethylene bis-12-hydroxystearamide to the first catalyst is 2.2-2.5:2.2-2.5:1.0:3.0-5.5; a weight ratio of the ethylene bis-12-hydroxystearamide to the first solvent is 1:8-10;in step S2a, the second catalyst is at least one of potassium carbonate and sodium carbonate;in step S2a, the second solvent is at least one selected from the group consisting of dimethyl sulfoxide, N,N-dimethylformamide, toluene, and N,N-dimethylacetamide;the halogenated olefin in step S2a is one selected from the group consisting of 3-bromo-1 propylene, 4-bromo-1-butene, 5-bromo-1-pentene, 6-bromo-1-hexene, 7-bromo-1-heptene, 8-bromo-1-octene, ...

Подробнее
Номер записи: 80
28-01-2021 дата публикации

Method for producing polyfunctional sulfur-containing epoxy compound

Номер: US20210024478A1
Автор: Hiroshi Horikoshi, Yousuke IMAGAWA
Принадлежит: Mitsubishi Gas Chemical Co Inc

The present invention makes it possible to provide a method for producing a polyfunctional sulfur-containing epoxy compound, the method being characterized in that a polyfunctional thiol is reacted with an epihalohydrin in the presence of a reducing agent to form a polyfunctional sulfur-containing halohydrin, which is then reacted with a basic compound. The reducing agent is preferably at least one selected from the group consisting of sodium borohydride, lithium borohydride, lithium aluminum hydride, diisobutylaluminum hydride, and hydrazine.

Подробнее
Номер записи: 81
04-02-2016 дата публикации

SUBSTITUTED 2-[PHENOXY-PHENYL]-1-[1,2,4]TRIAZOL-1-YL-ETHANOL COMPOUNDS AND THEIR USE AS FUNGICIDES

Номер: US20160029630A1
Автор: Boudet Nadege, Craig Ian Robert, Dietz Jochen, ESCRIBANO CUESTA Ana, Grammenos Wassilios, Grote Thomas, Haden Egon, Lauterwasser Erica May Wilson, Lohmann Jan Klaas, Mueller Bernd
Принадлежит: BASF SE

The present invention relates to substituted 2-[phenoxy-phenyl]-[1,2,4]triazol-1-yl-ethanol compounds of formula I as defined in the description, and the N-oxides, and salts thereof, their preparation and intermediates for preparing them. The invention also relates to the use of these compounds for combating harmful fungi and seed coated with at least one such compound and also to compositions comprising at least one such compound. 116-. (canceled)18. The compounds according to claim 17 , wherein Ris C-C-alkyl claim 17 , C--alkoxy-C-C-alkyl claim 17 , C-C-alkyl claim 17 , C-C-alkoxy-C-C-alkyl claim 17 , C-C-cycloalkyl-C-C-alkyl claim 17 , phenyl claim 17 , phenyl-C-C-alkyl claim 17 , phenyl-C-C-alkenyl or phenyl-C-C-alkyl claim 17 , wherein the aliphatic groups of Rmay carry one claim 17 , two claim 17 , three or up to the maximum possible number of identical or different groups Rwhich independently of one another are selected from OH claim 17 , halogen claim 17 , CN claim 17 , nitro claim 17 , C-C-cycloalkyl and C-C-halocycloalkyl and wherein the cycloalkyl and/or phenyl moieties of Rmay carry one claim 17 , two claim 17 , three claim 17 , four claim 17 , five or up to the maximum number of identical or different groups R.19. The compound according to claim 17 , wherein Ris C-C-alkyl claim 17 , C-C-alkoxy-C-C-alkyl claim 17 , C-C-alkyl claim 17 , C-C-alkoxy-C-C-alkyl claim 17 , C-C-cycloalkyl-C-C-alkyl claim 17 , phenyl claim 17 , phenyl-C-C-alkyl claim 17 , phenyl-C-C-alkenyl or phenyl-C-C-alkyl claim 17 , wherein the aliphatic groups of Rmay carry one claim 17 , two claim 17 , three or up to the maximum possible number of identical or different groups Rwhich independently of one another are selected from OH claim 17 , halogen claim 17 , CN claim 17 , nitro claim 17 , C-C-cycloalkyl and C-C-halocycloalkyl and wherein the cycloalkyl and/or phenyl moieties of Rmay carry one claim 17 , two claim 17 , three claim 17 , four claim 17 , five or up to the maximum number ...

Подробнее
Номер записи: 82
04-02-2016 дата публикации

Process for preparing cyclododecanone

Номер: US20160031784A1
Автор: Harald Haeger, Jens Doering, Juergen Herwig, Kévin Micoine, Luca Cameretti, Martin Roos, Ralf Meier
Принадлежит: EVONIK DEGUSSA GmbH

Cyclododecanone (CDON) is prepared by epoxidizing cyclododecene (CDEN) to epoxycyclododecane (CDAN epoxide), and rearranging the CDAN epoxide to CDON to obtain a mixture comprising said CDON and CDEN, wherein CDEN is separated from the CDON-containing mixture and sent to the epoxidation to CDAN epoxide in step a.

Подробнее
Номер записи: 83
04-02-2016 дата публикации

Dipeptide and tripeptide epoxy ketone protease inhibitors

Номер: US20160031934A1
Автор: David C. Moebius, Dustin McMinn, Henry Johnson
Принадлежит: Onyx Therapeutics Inc

Provided herein are dipeptide and tripeptide epoxy ketone protease inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula (X): and pharmaceutically acceptable salts and compositions including the same. The compounds and compositions provided herein may be used, for example, in the treatment of proliferative diseases including cancer and autoimmune diseases.

Подробнее
Номер записи: 84
01-02-2018 дата публикации

METHOD FOR THE EPOXIDATION OF AN OLEFIN WITH HYDROGEN PEROXIDE

Номер: US20180030012A1
Автор: ANDRÉ Joao, Imm Sebastian, PASCALY Matthias, Stock Jürgen
Принадлежит: EVONIK DEGUSSA GmbH

In the method for the epoxidation of an olefin, the olefin is continuously reacted with hydrogen peroxide in a mixed reactor in the presence of a water soluble epoxidation catalyst, comprising a manganese complex, the reaction is carried out in a reaction mixture comprising an aqueous liquid phase and an organic liquid phase with mixing of the liquid phases, reaction mixture is continuously withdrawn from the mixed reactor and separated into a separated aqueous phase and a separated organic phase, and part of the separated aqueous phase is continuously recycled into the mixed reactor, with the combined hold-up time of aqueous phase in withdrawing, separating phases and recycling aqueous phase being kept at less than 15 minutes. 113-. (canceled)14. A method for the epoxidation of an olefin , comprising:a) continuously reacting the olefin with hydrogen peroxide in a mixed reactor in the presence of a water soluble epoxidation catalyst comprising a manganese complex, wherein the reaction is carried out in a reaction mixture comprising an aqueous liquid phase and an organic liquid phase with mixing of the liquid phases;b) continuously withdrawing reaction mixture from the mixed reactor and separating the withdrawn reaction mixture into a separated aqueous phase and a separated organic phase; andc) continuously recycling part of the separated aqueous phase into the mixed reactor;wherein the combined hold-up time of aqueous phase in steps b) and c), defined as the ratio of the total volume occupied by aqueous phase in steps b) and c) to the volumetric flow rate of recycled separated aqueous phase, is less than 15 minutes.15. The method of claim 14 , wherein in step b) the withdrawn reaction mixture is separated with a centrifuge.16. The method of claim 15 , wherein the centrifuge provides an acceleration of at least 50 000 ms.17. The method of claim 15 , wherein the centrifuge is a conical plate centrifuge.18. The method of claim 14 , wherein step c) comprises ...

Подробнее
Номер записи: 85
31-01-2019 дата публикации

ORGANIC COMPOUND, THREE-DIMENSIONAL ORGANIC FRAMEWORK FORMED BY USING ORGANIC COMPOUND, SEPARATION SIEVE AND OPTICAL LAYER, WHICH COMPRISE ORGANIC FRAMEWORK, AND OPTICAL DEVICE COMPRISING OPTICAL LAYER AS OPTICAL AMPLIFICATION LAYER

Номер: US20190031586A1
Автор: Choi Kyounghwan, SUH Donghack
Принадлежит: Industry-University Cooperation Foundation Hanyang University

An organic compound, a three-dimensional organic structure formed by using the organic compound, a separation sieve and an optical layer having the organic structure, and an optical device having the optical layer as an optical amplification layer are provided. The organic structure includes a plurality of organic molecules self-assembled by non-covalent bonding. Each of the unit organic molecules has an aromatic ring, a first pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring, and a second pair of substituents being connected to immediately adjacent positions of remaining substitutable positions of the aromatic ring. The unit organic molecules are self-assembled by van der Waals interaction, London dispersion interaction or hydrogen bonding between the first and the second pairs of the substituents and by pi-pi interactions between the aromatic rings. 147-. (canceled)48. A three-dimensional organic structure comprising a plurality of unit organic molecules which are self-assembled to form the three-dimensional organic structure ,wherein each of the unit organic molecules has at least one aromatic ring, a first pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring, and a second pair of substituents being connected to immediately adjacent positions of substitutable positions of the aromatic ring,{'sub': c', 'd', 'e', 'c', 'd', 'e', 'c', 'd', 'e', 'c', 'd', 'e', 'c', 'd', 'e', 'a', 'c', 'd', 'e', '2, 'wherein the substituents have terminal groups, independently, including a group selected from the group consisting of —CRRR, —OH, —COOH, —CHO, —SH, —COCRRR, —COOCRRR, —CR═CRR, —CN, —N═C═O, —C═N═N—CRRR, —C≡CR, —NHCRRR, or —NH,'}wherein the unit organic molecules contained in one layer of the three-dimensional structure are self-assembled by van der Waals interaction, London dispersion interaction or hydrogen bonding between the terminal ...

Подробнее
Номер записи: 86
31-01-2019 дата публикации

A PROCESS FOR PREPARATION OF AN AROMATIC N-GLYCIDYLAMINE

Номер: US20190031632A1
Автор: Kathalewar Mukesh, Lalani Alif, More Vishnu, Samant Prashant, Singh Ashok Kumar
Принадлежит:

A process for preparing an aromatic N-glycidylamine comprising a step of heating a mixture of an amine having at least one aromatic aminohydrogen atom with at least 0.7 equivalent of epichlorohydrin per aminohydrogen equivalent of the amine in presence of a catalyst dissolved in an inert organic solvent, at a pressure in a range of 200 mbar to 600 mbar; and adding a base to the mixture at a pressure in a range of 200 mbar to 600 mbar to facilitate dehydrochlorination of product of the previous step to obtain the aromatic N-glycidylamine. 1. A process for preparing an aromatic N-glycidylamine comprising:a) heating a mixture of an amine having at least one aromatic aminohydrogen atom with at least 0.7 equivalent of epichlorohydrin per aminohydrogen equivalent of the amine in presence of a catalyst dissolved in an inert organic solvent, at a pressure in a range of 200 mbar to 600 mbar; andb) adding a base to the mixture at a pressure in a range of 200 mbar to 600 mbar to facilitate dehydrochlorination of product of step (a) to obtain the aromatic N-glycidylamine.2. The process as claimed in claim 1 , wherein the amine is heated with at least 0.8 to 1.5 equivalent of the epichlorohydrin per aminohydrogen equivalent of the amine.3. The process as claimed in claim 1 , wherein the heating of the mixture is performed at a temperature in a range of 50° C. to 100° C.4. The process as claimed in claim 1 , wherein the heating of the mixture is carried out for 2 hours to 7 hours.5. The process as claimed in claim 1 , wherein the heating of the mixture is carried out for 2 hours to 4 hours.6. The process as claimed in claim 1 , wherein the inert organic solvent is selected from a group consisting of methoxyethanol claim 1 , 2-butoxyethanol claim 1 , isodecanol claim 1 , ethyleneglycol claim 1 , diethyleneglycol claim 1 , N-methylpyrrolidone claim 1 , gamma butyrolactone claim 1 , benzyl alcohol claim 1 , dibutyl phthalate claim 1 , butane-1 claim 1 ,4-diol claim 1 , ethyl methyl ...

Подробнее
Номер записи: 87
04-02-2021 дата публикации

Cosmetic Composition Comprising Vetiver Root Extract

Номер: US20210030663A1
Автор: Lambert Carole, REYNAUD Romain, SCANDOLERA Amandine
Принадлежит:

A cosmetic composition is provided, which comprises a carrier and a Vetiver root extract, in particular an extract from exhausted Vetiver root. This composition provides a stimulation of sebum production, stimulation of sebum antimicrobial, lipids production, activation of adipocytes volume increase, skin hydration, skin tonicity booster, skin fatigue reduction, perilabial wrinkles reduction, skin replumping, and fragrance long-lastingness enhancement. 1. A cosmetic composition comprising a carrier and at least one active cosmetic ingredient , wherein the at least one active cosmetic ingredient comprises a Vetiver root extract.2. The cosmetic composition according to claim 1 , wherein the cosmetic composition is a skin care composition.3. The cosmetic composition according to claim 1 , wherein the at least one active cosmetic ingredient comprises an aqueous extract of Vetiver root.4. The cosmetic composition according to claim 1 , wherein the at least one active cosmetic ingredient comprises an extract of exhausted Vetiver root.5. A method of preparing an active cosmetic ingredient claim 1 , comprising the step of: extracting Vetiver root.6. The method according to claim 5 , comprising the steps of:(i) providing exhausted Vetiver root; and(ii) extracting the exhausted Vetiver root.7. The method according to claim 5 , wherein the extraction is performed using water.8. (canceled)9. A method of stimulating the sebum production claim 1 , of stimulating sebum antimicrobials claim 1 , of stimulating the lipids production claim 1 , of activating the adipocytes volume increase claim 1 , of improving the skin hydration claim 1 , of boosting the skin tonicity claim 1 , of reducing skin fatigue claim 1 , of reducing perilabial wrinkles claim 1 , of replumping skin claim 1 , and/or of enhancing fragrance long-lastingness claim 1 , the method comprising the step of: applying the cosmetic composition of to human skin. The present invention relates to cosmetic compositions ...

Подробнее
Номер записи: 88
31-01-2019 дата публикации

PROCESS FOR PREPARING BIPHENYL COMPOUNDS

Номер: US20190032098A1
Автор: CARLOTTI Stéphane, CRAMAIL Henri, GRAU Etienne, GRELIER Stéphane, LLEVOT Audrey
Принадлежит:

A process is provided for preparing a compound having the formula (I): 2. The process of claim 1 , wherein the water-miscible solvent is acetone.3Trametes versicolor.. The process of claim 1 , wherein the laccase is from4. The process of claim 1 , wherein the amount of laccase for one gram of compound of formula (II) is from 1.5 mg to 75 mg.5. The process of claim 1 , wherein the solution of the compound of formula (II) in a water-miscible solvent is prepared by adding said compound of formula (II) in said water-miscible solvent claim 1 , and adding a buffer solution.6. The process according to claim 5 , wherein the amount of water-miscible solvent is comprised between 5% and 10% of volume in comparison with the total volume of the mixture formed by said solvent and the buffer solution.7. The process of claim 1 , wherein the addition of an oxygen source according to a) is carried out for a sufficient time to saturate the solution in dissolved oxygen.8. The process of claim 1 , wherein the solution of the compound of formula (II) in the water-miscible solvent used for b) is saturated in oxygen.9. The process of claim 1 , wherein the pH of the solution of the compound of formula (II) in the water-miscible solvent is comprised between 4 and 7.10. The process of claim 1 , wherein step c) is a step of recovering the compound of formula (I) by centrifugation or filtration.11. The process of claim 1 , wherein the amount of laccase for one gram of compound of formula (II) is from 3 mg to 15 mg.12. The process of claim 5 , wherein the buffer solution is a sodium acetate buffer.13. The process of claim 7 , wherein the addition of an oxygen source according to step a) is carried out for 5 minutes. This application is a continuation of U.S. patent application Ser. No. 15/516,318, filed Mar. 31, 2017, which is a 371 application of International Application PCT/EP2015/072957, filed Oct. 5, 2015, and which claims the benefit of European Patent Office application Serial No. ...

Подробнее
Номер записи: 89
30-01-2020 дата публикации

SIMPLE OXIDATIVE FUNCTIONALIZED OF ALKYL ARYL KETONES

Номер: US20200031790A1
Автор: Sommerlade Reinhard
Принадлежит:

The present invention refers to a process for reacting an alkyl aryl ketone obtaining thereby the corresponding aryl oxirane or α-functionalized alkyl aryl ketal, the aryl oxirane or α-functionalized alkyl aryl ketal obtained by the process as well as the α-functionalized ketone obtained by the process. 2: The process according to claim 1 , wherein Rand Rare the same.3: The process according to claim 2 , wherein Rand Rare selected from H and linear or branched C-C-alkyl.4: The process according to claim 1 , wherein Rand Rare different and are independently selected from H and linear or branched C-C-alkyl.5: The process according to claim 1 , wherein Rand Rform a C-C-cycloalkyl together with the connecting C atom.6: The process according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare the same.7: The process according to claim 6 , wherein R claim 6 , R claim 6 , R claim 6 , Rand Rare selected from H and linear or branched C-C-alkyl.8: The process according to claim 1 , wherein R claim 1 , R claim 1 , R claim 1 , Rand Rare different and at least one of them is selected from linear or branched C-C-alkyl claim 1 , linear or branched C-C-alkenyl claim 1 , C-C-alkoxy claim 1 , C-C-alkenyloxy claim 1 , C-C-alkenylarylalkoxy or N(R)or SR claim 1 , wherein Ris selected from linear or branched C-C-alkyl or linear or branched C-C-alkenyl or Rform a C-C-alicyclic system together with the connecting N atom.9: The process according to claim 1 , wherein one of R claim 1 , R claim 1 , R claim 1 , Rand Ris linear or branched C-C-alkenyl C-C-alkenyloxy claim 1 , C-C-alkenylarylalkoxy claim 1 , or N(R)or SRwith Rbeing selected from linear or branched C-C-alkyl or linear or branched C-C-alkenyl or Rform a C-C-alicyclic system together with the connecting N atom; and the remaining ones are independently selected from H and linear or branched C-C-alkyl.10: The process according to claim 1 , wherein two or three of R claim 1 , R claim 1 , R claim 1 , Rand Rare linear or ...

Подробнее
Номер записи: 90
30-01-2020 дата публикации

SHIKIMATE ANALOGUES AND METHODS OF USE

Номер: US20200031791A1
Автор: Cichewicz Robert, Du Lin, NICHOLAS KEN, You Jianlan
Принадлежит:

The present disclosure, in at least certain embodiments, is directed to shikimate (shikimic acid) analogues and compositions thereof, devices and kits which contain the shikimate analogues or compositions thereof, and methods of use of the compounds and compositions for treating and neutralizing irritant or odoriferous compounds on animate or inanimate surfaces or in atmospheres. Examples of such irritant and odoriferous compounds include urushiols from poison ivy, oak, and sumac and mercaptans of skunk spray. 2. The composition of claim 1 , wherein the at least one shikimate analogue has Structural Formula I claim 1 , wherein X=O claim 1 , Ris (C1-C8)alkyl claim 1 , Ris absent claim 1 , Ris selected from the group consisting of fluoro claim 1 , chloro claim 1 , bromo claim 1 , iodo claim 1 , and (C1-C8)alkoxy claim 1 , R=OH claim 1 , R=OH claim 1 , and R=OH.3. The composition of claim 1 , wherein the at least one shikimate analogue has Structural Formula I claim 1 , wherein X=O claim 1 , R=CH claim 1 , Ris absent claim 1 , R=Cl claim 1 , R=OH claim 1 , R=OH claim 1 , and R=OH (Pericosine A).4. The composition of claim 1 , wherein the at least one shikimate analogue has Structural Formula I claim 1 , wherein X=O claim 1 , R=CH claim 1 , Ris absent claim 1 , R=OCH claim 1 , R=OH claim 1 , R=OH claim 1 , and R=OH (Pericosine C).5. The composition of claim 1 , wherein the at least one shikimate analogue is selected from the group consisting of Pericosine A claim 1 , Pericosine B claim 1 , Pericosine C claim 1 , and Pericosine D.6. The composition of claim 1 , wherein at least one of the one or more secondary compounds is not methanol claim 1 , ethanol claim 1 , or a propanol.7. The composition of claim 1 , wherein the one or more secondary compounds is selected from the group consisting of organic bases claim 1 , inorganic bases claim 1 , and organic/inorganic bases.8. The composition of claim 1 , wherein the one or more secondary compounds is an amine or a salt ...

Подробнее
Номер записи: 91
31-01-2019 дата публикации

Electrolysis System and Method for Electrochemical Ethylene Oxide Production

Номер: US20190032228A1
Автор: Bernhard Schmid, Christian Reller, Günter Schmid, Ralf Krause
Принадлежит: SIEMENS AG

An example electrolysis system for the electrochemical production of ethylene oxide includes an electrolysis cell having an anode in an anode space and a cathode in a cathode space and a gas separation element. The cathode space has a first inlet for carbon monoxide and/or carbon dioxide. The anode space is integrated into an anolyte circuit and the cathode space is integrated into a catholyte circuit. The catholyte circuit has a first product outlet for a reduction product joined to a first connecting conduit connected to the anolyte circuit. The anode space is configured for bringing a reduction product introduced via the first connecting conduit into contact with an oxidation product.

Подробнее
Номер записи: 92
04-02-2021 дата публикации

CRYSTALLINE SALTS OF PEPTIDE EPOXYKETONE IMMUNOPROTEASOME INHIBITOR

Номер: US20210032232A1
Автор: Dalziel Sean, JOHNSON Henry, Lewis Evan, McMinn Dustin
Принадлежит:

Provided herein is a peptide epoxyketone immunoproteasome inhibitor, crystal forms, salts, and processes for making the same, and formulations thereof. 2. The crystalline salt of claim 1 , wherein Xcomprises maleate claim 1 , fumarate claim 1 , oxalate claim 1 , malate claim 1 , sulfate claim 1 , methanesulfonate claim 1 , 2-naphthalenesulfonate claim 1 , phosphate claim 1 , halide claim 1 , tartrate claim 1 , citrate claim 1 , tosylate claim 1 , propionate claim 1 , or benzoate.3. The crystalline salt of or claim 1 , as a salt hydrate.4. The crystalline salt of or claim 1 , wherein Xcomprises maleate.5. The crystalline salt of claim 4 , wherein the crystalline salt is the monomaleate salt.6. The crystalline salt of or claim 4 , having an X-ray powder diffraction (“XRPD”) pattern comprising peaks at about 6.9 claim 4 , 17.3 claim 4 , and 17.8±0.2° 2θ using Cu Kα radiation (“Form A”).7. The crystalline salt of further comprising peaks at about 4.9 claim 6 , 6.8 claim 6 , and 7.7±0.2° 2θ using Cu Kα radiation.8. The crystalline salt of further comprising peaks at about 10.9 claim 7 , 12.4 claim 7 , 13.5 claim 7 , 14.2 claim 7 , 16.1 claim 7 , 16.4 claim 7 , 18.5 claim 7 , 21.0 claim 7 , 22.0 claim 7 , 23.4 claim 7 , 23.7 claim 7 , 24.5 claim 7 , and 25.2±0.2° 2θ using Cu Kα radiation.9. The crystalline salt of any one of - having an XRPD pattern substantially as shown in .10. The crystalline salt of any one of - claim 7 , having a differential scanning calorimetry (“DSC”) thermogram substantially as shown in .11. The crystalline salt of or claim 7 , having an XRPD pattern comprising peaks at about 7.2 claim 7 , 18.4 claim 7 , and 22.0±0.2° 2θ using Cu Kα radiation (“Form B”).12. The crystalline salt of further comprising peaks at about 6.8 claim 11 , 6.6 claim 11 , 13.6 claim 11 , 22.0 claim 11 , 17.4 claim 11 , 14.5 claim 11 , 18.0 claim 11 , and 5.0±0.2° 2θ using Cu Kα radiation.13. The crystalline salt of any one of - or - claim 11 , having an XRPD pattern ...

Подробнее
Номер записи: 93
05-02-2015 дата публикации

REGULATION OF CHOLESTEROL HOMEOSTASIS

Номер: US20150038566A1
Автор: Taylor Richard
Принадлежит: University of Notre Dame du Lac

The invention provides novel compounds of Formulas (I)-(IV), as described herein. Also provided are compositions of these compounds, method of making the compounds, and methods of using the compounds. The compounds can be used to regulate cholesterol homeostasis and to treat conditions and diseases associated with cholesterol homeostasis, including lysosomal lipid storage disorders such as Niemann-Pick Disease type C. 5. The method of wherein the olefin cross metathesis coupling conditions comprise the presence of a Grubbs-Hoveyda catalyst.6. The method of wherein the Grubbs-Hoveyda catalyst is the second generation Grubbs-Hoveyda catalyst.11. The method of wherein the patient is human.12. The method of wherein the lysosomal lipid storage disorder involves cellular cholesterol buildup.13. The method of wherein the cellular cholesterol buildup occurs in neuronal cells.14. The method of wherein the lysosomal lipid storage disorder is Niemann Pick Type-C disease.15. The method of wherein the method comprises treating a neurodegenerative disease.16. The method of wherein the neurodegenerative disease is Niemann Pick Type-C disease.17. The method of wherein the neurodegenerative disease is Alzheimer's disease. This application is a continuation of U.S. patent application Ser. No. 13/961,659, filed Aug. 7, 2013, issued as U.S. Pat. No. 8,865,761, and this application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/742,290, filed Aug. 7, 2012, the specifications of which are herein incorporated by reference.Niemann-Pick Disease type C (NPC) is a neurovisceral lysosomal lipid storage disorder that has a wide clinical spectrum. The disease may cause rapid fatality in neonates, or chronic neurodegenerative symptoms in children and adults. It can present hepatosplenomegaly (enlarged liver and spleen) in infants, children or adults. NPC is characterized by eye movement abnormalities, dysphagia (difficulty in swallowing) and dysarthria ( ...

Подробнее
Номер записи: 94
08-02-2018 дата публикации

C14-HYDROXYL ESTERIFIED AMINO ACID DERIVATIVE OF TRIPTOLIDE, AND PREPARATION METHOD AND USE THEREOF

Номер: US20180036277A1
Автор: Jiang Hongjian, Xu Rongzhen
Принадлежит:

The present invention belongs to the field of natural medicines and medicinal chemistry, and relates to novel esterified amino acid derivatives of triptolide of general formula I and general formula II or pharmaceutically acceptable adducts, complexes, salts, and catabolites and metabolites thereof, preparation methods of these compounds, pharmaceutical compositions comprising the compound, and uses thereof in preparing drugs against tumors, immune diseases, or diseases related to abnormal expression of XPB or Pol II or oncogene c-myc. 2. A pharmaceutically acceptable adduct or complex of the C14-hydroxyl esterified amino acid derivative of triptolide according to .3. A pharmaceutically acceptable salt of the C14-hydroxyl esterified amino acid derivative of triptolide according to .4. A catabolite and a metabolite of the C14-hydroxyl esterified amino acid derivative of triptolide according to .5. A pharmaceutically acceptable adduct claim 1 , complex claim 1 , salt claim 1 , and catabolite and metabolite of the C14-hydroxyl esterified amino acid derivative of triptolide according to claim 1 , wherein Rand Rare selected from substituted or unsubstituted C-Calkyl claim 1 , substituted or unsubstituted C-Calkenyl claim 1 , substituted or unsubstituted C-Cconjugated alkenyl claim 1 , substituted or unsubstituted C-Ccycloalkyl or cycloalkenyl claim 1 , substituted or unsubstituted aryl claim 1 , substituted or unsubstituted heterocyclyl and aromatic heterocyclyl claim 1 , and substituted or unsubstituted amino acid side-chain alkyl claim 1 , the amino acid may be racemic claim 1 , or may be optically pure levorotary or dextrorotary; the substituents are selected from halogen claim 1 , amino claim 1 , C-Csubstituted amino claim 1 , nitro claim 1 , cyano claim 1 , hydroxyl claim 1 , C-Calkoxy claim 1 , mercapto claim 1 , and C-Calkylthio; Rand R claim 1 , Rand Rare or are not protecting groups; Rand Rare the same or different; Rand Rare the same or different; wherein R ...

Подробнее
Номер записи: 95
08-02-2018 дата публикации

Process for the regeneration of a titanium zeolite catalyst for propylene epoxidation

Номер: US20180036723A1
Автор: Alexander Schroeder, Andrei-Nicolae Parvulescu, Daniel Urbanczyk, Dominic RIEDEL, Joaquim Henrique Teles, Luise Spiske, Meinolf Weidenbach, Ulrich Mueller, Ulrike Wegerle, Werner J. Witzl
Принадлежит: BASF SE, Dow Global Technologies LLC

The invention relates to process for the regeneration of a catalyst comprising a titanium containing zeolite as catalytically active material comprising a stage comprising introducing a feed stream comprising propene, hydrogen peroxide or a hydrogen peroxide source, and an organic solvent into a reactor containing a catalyst comprising the titanium containing zeolite, subjecting the feed stream in the reactor to epoxidation conditions in the presence of the catalyst, removing a product steam comprising propylene oxide and the organic solvent from the reactor, stopping introducing the feed stream, washing the catalyst with a liquid aqueous system and calcining the washed catalyst.

Подробнее
Номер записи: 96
09-02-2017 дата публикации

BETA-SUBSTITUTED BETA-AMINO ACIDS AND ANALOGS AS CHEMOTHERAPEUTIC AGENTS AND USES THEREOF

Номер: US20170036992A1
Автор: Fischer Wolf-Nicolas, Jandeleit Bernd, Koller Kerry J., Ringold Gordon
Принадлежит:

β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres are selective LAT1/4F2hc substrates and exhibit rapid uptake and retention in tumors expressing the LAT1/4F2hc transporter. Methods of synthesizing the β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and methods of using the compounds for treating cancer are also disclosed. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs exhibit selective uptake in tumor cells expressing the LAT1/4F2hc transporter and accumulate in cancerous cells when administered to a subject in vivo. The β-substituted β-amino acid derivatives and β-substituted β-amino acid analogs and (bio)isosteres exhibit cytotoxicity toward several tumor types. 2. The compound of claim 1 , wherein one of R claim 1 , R claim 1 , R claim 1 , and Rcomprises a chemotherapeutic moiety.4. The compound of claim 1 , wherein the chemotherapeutic moiety is a moiety of Formula (2a):{'br': None, 'sup': 11', '11', '9', '11', '11', '9, 'sub': 2', '2', '2', '2, '-A-NQ(-Z—C(R)—C(R)—R)(—C(R)—C(R)—R)\u2003\u2003(2a)'}wherein,{'sub': 2', '2', '2', '2, 'A is selected from a bond (“—”), methylene (—CH—), oxygen (—O—), methyleneoxy (—CH—O—), carbonyl (—C(═O)—), methylenecarbonyl (—CH—C(═O)—), oxycarbonyl (—O—C(═O)—), and methyleneoxycarbonyl (—CH—O—C(═O)—);'}Z is selected from a bond (“—”) and oxygen (—O—);{'sup': '−', 'Q is selected from —O (a negatively charged oxygen atom that is bound to a positively charged nitrogen atom) and a free electron pair (:);'}{'sup': '11', 'each Ris independently selected from hydrogen and deuterio; and'}{'sup': 9', '40', '40', '40', '40', '40', '40, 'sub': 2', '1-4', '1-4', '2', '1-4', '2', '6-10, 'each Ris independently selected from fluoro (—F), chloro (— ...

Подробнее
Номер записи: 97
09-02-2017 дата публикации

Hydroxamic acids and uses thereof

Номер: US20170036996A1
Автор: Alan Thomas Johnson, Henry Lee Jackson, Sean O&#39;Malley, Seong Jin Kim
Принадлежит: Hawaii Biotech Inc

Compounds of formula I are provided: R 1 is an alkoxy or O(CH 2 ) p X, p is an integer from 2 to 3 and X is OH, NH 2 , or CO 2 H, m is an integer from 0 to 5, n is an integer from 0 to 5, each R 2 is independently selected from hydrogen, alkenyl, hydroxyalkyl, alkoxymethyl, heterocyclyl, hetereocyclylmethyl, amino, amido, hydroxamido, any of which may be optionally substituted with one or more of acyl, alkyl, alkoxy, hydroxyalkyl, or halogen, each R 3 is independently selected from hydrogen, halogen, alkyl, alkenyl, carboxy, hydroxymethyl, amido, and at least one of R 2 and R 3 is not hydrogen.

Подробнее
Номер записи: 98
09-02-2017 дата публикации

Method of electroplating photoresist defined features from copper electroplating baths containing reaction products of imidazole compounds, bisepoxides and halobenzyl compounds

Номер: US20170037528A1
Автор: Erik Reddington, Julia KOZHUKH, Julia WOERTINK, Mark Lefebvre, Matthew Thorseth, Yi Qin, Zuhra Niazimbetova
Принадлежит: Dow Global Technologies LLC, Rohm and Haas Electronic Materials LLC

Electroplating methods enable the plating of photoresist defined features which have substantially uniform morphology. The electroplating methods include copper electroplating baths with reaction products of imidazole compounds, bisepoxides and halobenzyl compounds to electroplate the photoresist defined features. Such features include pillars, bond pads and line space features.

Подробнее
Номер записи: 99
24-02-2022 дата публикации

SYNTHETIC METHODS

Номер: US20220055999A1
Автор: Barcan Gregg, Guo Jiasheng, Morgan Christopher W., Roiban Gheorghe D., Sutton Peter W.
Принадлежит:

Methods for the preparation of the following compound are disclosed. 1. A tablet comprising the compound GSK2330672:wherein the compound has been prepared by a synthesis comprising the step of preparation of intermediate A, (R)-2-butyl-2-ethyloxiranefollowed by conversion of (R)-2-butyl-2-ethyloxirane through one or more steps to GSK2330672. The present invention relates to improved synthetic methods for certain compounds that are useful in the treatment and prevention of metabolic disorders, including diabetes mellitus (Type I and Type II), obesity, and for the prophylaxix and/or treatment of a liver disease.Patent publication WO 2011/137,135 discloses, among other compounds, the following IBAT inhibitor compound. This patent publication also discloses methods of synthesis of the compound.The preparation of the above compound is also disclosed in J. Med. Chem, Vol 56, pp 5094-5114 (2013) and in J. Org. Chem., Vol 78, pp 12726-12734 (2013). This compound is also known as GSK2330672 and sometimes abbreviated as GSK672.This compound is in clinical trial for the prophylaxix and/or treatment of a cholestatic liver disease and the associated pruritis.Briefly, in a first aspect, the present invention discloses an improved synthesis of the compoundcomprising the step of preparation of intermediate A, (R)-2-butyl-2-ethyloxiraneBriefly, in a second aspect, the present invention discloses an improved synthesis of the compoundcomprising the step of preparation of intermediate H depicted belowIn another aspect the present invention provides a tablet comprising the compound GSK2330672.In another aspect the present invention provides a method for treating a cholestatic liver disease and/or the associated pruritis, comprising administration of the tablet of the present invention.Preferably, the first aspect of the invention as described above, comprises the kinetic resolution of racemic 2-butyl-2-ethyloxirane using an epoxide hydrolase to afford (R)-2-butyl-2-ethyloxirane ( ...

Подробнее
Номер записи: 100